<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1410246041
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEPAKINE 200MG-ML SOLU.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALPROATE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sanofi &#x130;la&#xE7; Sanayi ve Tic A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sanofi İlaç Sanayi ve Tic A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis FRANCE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AG01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: ANTIEPILEPTICS, ATC code: N03AG01.<br />Depakine belongs to a family of medicines called antiepileptics<br />This medicine is used to treat various types of seizures in adults and children. It is also used in children to prevent fever-related seizures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>not take Depakine 200 mg/mL oral solution:</strong><br />&bull;if you are pregnant, unless no other epilepsy treatment works for you (see below &ldquo;Pregnancy, breast-feeding and fertility &ndash; Important advice for women&rdquo;),<br />&bull;if you are a woman able to have a baby, unless no other epilepsy treatment works for you and you are able to follow all the steps of the Pregnancy Prevention Plan (see below &ldquo;Pregnancy, breastfeeding and fertility &ndash; Important advice for women&rdquo;),<br />&bull; if you are allergic to the active substance (sodium valproate) or any of the other ingredients of this medicine (listed in section 6),<br />&bull; if you are allergic to a medicine in the same family as valproate (valproate semisodium, valpromide),<br />&bull; if you have liver disease (acute or chronic hepatitis),<br />&bull; if you or a member of your family have ever had serious liver disease, particularly related to use of a medicine,<br />&bull; if you have hepatic porphyria (hereditary liver disease),<br />&bull; if you have a genetic problem causing a mitochondrial disorder (e.g. Alpers-Huttenlocher Syndrome),<br />&bull; if you have a known metabolic disorder, such as a urea cycle disorder (see &quot;Warnings and precautions&quot;),<br />&bull; if you are currently taking the following medicine:<br />o St. John&rsquo;s Wort (plant used to treat depression).<br /><strong>Warnings and precautions</strong><br />This medicine can, in very rare cases, cause liver damage (hepatitis) or pancreas damage (pancreatitis), which can be serious and life-threatening.<br />Your doctor will prescribe blood tests to regularly monitor your liver function, particularly during the first 6 months of treatment.<br />Inform your doctor immediately if any of the following signs appear:<br />&bull; sudden fatigue, loss of appetite, exhaustion, drowsiness, swelling of the legs, general malaise, &bull; repeated vomiting, nausea, stomach or bowel pain, yellow colour of the skin or eyes (jaundice),<br />&bull; recurrence of epileptic seizures even though you are taking your treatment correctly.<br />&bull; Before taking this medicine, tell your doctor if you have kidney disease (renal insufficiency), systemic lupus erythematosus (rare disease) or hereditary enzyme deficiencies, particularly an enzyme deficiency of the urea cycle that can cause increased amounts of ammonium in the blood, or a genetic problem causing a mitochondrial disorder (including in your family).<br />&bull; If you are scheduled to have surgery, you must inform the medical personnel that you are taking this medicine.<br />&bull; At the start of treatment, your doctor will check that you are not pregnant and that you have a method of contraception (see &ldquo;Pregnancy&rdquo;).<br />&bull; As with other antiepileptics, taking this medicine can lead to your seizures worsening or becoming more frequent; you may even experience a different type of seizure.<br />&bull; This medicine can cause weight gain. Your doctor will recommend that you take certain dietary measures and will monitor your weight.<br />&bull; Self-destructive or suicidal thoughts have also been observed in a small number of people treated with antiepileptics such as Depakine. If you have these kinds of thoughts, contact your doctor immediately.<br />&bull; If you have carnitine palmitoyltransferase (CPT) type II deficiency (hereditary metabolic disease), the risk of developing serious muscle problems (rhabdomyolysis) is higher with this medicine.<br />&bull; Inform your doctor if you have symptoms such as tremor, stiffness of the limbs and difficulty walking (extrapyramidal disorders) or memory and mental capacity disorders. He or she will try to find out whether they are caused by an underlying disease or by Depakine 200 mg/mL oral solution. It may be necessary to stop treatment.<br />Inform your doctor if your child is taking another antiepileptic treatment or has another neurological or metabolic disease or severe forms of epilepsy.<br /><strong>Other medicines and Depakine 200 mg/mL oral solution</strong><br />Some medicines may influence the effect of valproate and vice versa.<br /><strong>You must never take this medicine if you are taking the following medicine:</strong><br />&bull; St. John&#39;s Wort (plant-based medicine used to treat depression).<br /><strong>Do not take this medicine, unless stated otherwise by your doctor or pharmacist, if you take, have recently taken, or may take the following medicines:</strong><br />&bull; Lamotrigine (another medicine used to treat epileptic seizures); &bull; Penems (carbapenems) (antibiotics used to treat bacterial infections).<br /><strong>Tell your doctor if you are taking:</strong><br />&bull; Acetazolamide-containing medicines (medicines used to lower eye pressure or carbon dioxide levels in the blood).<br />&bull; Antibiotics (medicines containing aztreonam or rifampicin).<br />&bull; Other antiepileptic medicines (medicines containing carbamazepine, felbamate, phenytoin, fosphenytoin, primidone, phenobarbital, rufinamide, topiramate or zonisamide).<br />&bull; Nimodipine: Depakine can increase the effects of nimodipine (medicine used to prevent complications that can occur after bleeding in the brain).<br />&bull; Oestrogen-containing products (including some birth control pills).<br />&bull; Propofol (anaesthetic medicine).<br />&bull; Zidovudine-containing medicines (medicines used to treat HIV infection (Human Immunodeficiency Virus)).<br />&bull; Lithium-containing medicines (medicines used to treat mood disorders).<br />&bull; medicines containing metamizole (medicines used to treat pain and fever).<br />&bull; salicylates (including aspirin);<br />&bull; cannabidiol (used to treat epilepsy and other illnesses).<br />Specifically in children under 3 years of age, you must avoid giving medicines that contain salicylates (including aspirin) during treatment.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br /><strong>Depakine 200 mg/mL oral solution with food, drink and alcohol</strong><br />Use of alcoholic beverages is not recommended during treatment with Depakine.<br /><strong>Pregnancy, breast-feeding and fertility<br /><u>Pregnancy</u></strong><br /><strong>Important advice for women<br />Valproate is harmful to unborn babies if taken during pregnancy. Therefore:<br />&bull; If you are a female child, female adolescent or woman of childbearing age, your doctor may not prescribe valproate for you unless other treatments are ineffective or not tolerated. If no other treatment is possible, valproate will be prescribed for you and dispensed under the very strict conditions described below.<br />&bull; Make sure that you have read the Patient Guide given to you by your doctor. Your doctor will discuss the Annual Risk Acknowledgment Form with you and ask you to sign and keep it. You must show it to the pharmacist every time you pick up your medicine, along with the&nbsp;doctor&rsquo;s prescription. This Form certifies that the risks have been explained to you and that you agree to comply with the conditions below. Your pharmacist will also give you a Patient Card to remind you of the risks associated with taking valproate during pregnancy.</strong><br />You must not take Depakine:<br />&bull; if you are pregnant, unless no other epilepsy treatment works for you,<br />&bull; if you are a woman of childbearing age, unless no other epilepsy treatment works for you and you are able to follow all the steps of the Pregnancy Prevention Plan.<br /><em><u>The risks of valproate when taken during pregnancy</u></em><br />&bull; Talk to your doctor immediately if you are planning to have a baby, are pregnant or think you might be pregnant.<br />&bull; Valproate carries a risk for the unborn baby if taken during pregnancy. The higher the dose, the higher the risks but all doses carry a risk, including when valproate is used in combination with other medicines to treat epilepsy.<br />&bull; When taken by pregnant women, valproate can cause serious birth defects, and can harm the development (intellectual, motor, behavioural) of the child as it grows.<br />&bull; The most common birth defects which have been reported include spina bifida (where the bones of the spine are not properly developed); facial, upper lip, palate and skull malformations; heart, kidney, urinary tract and sexual organ malformations; limb defects and multiple associated malformations affecting various organs and parts of the body. Birth defects can lead to disabilities that can be severe.<br />&bull; Hearing disorders and hearing loss have been reported in children exposed to valproate during pregnancy.<br />&bull; Eye malformations have been reported in children exposed to valproate during pregnancy in association with other congenital malformations. These eye malformations can affect vision.<br />&bull; If you take valproate during pregnancy you have a higher risk than other women of having a child with birth defects that require medical treatment. Because valproate has been used for many years <strong>we know that in women who take valproate around 11 babies in every 100 will have birth defects. This compares to 2-3 babies in every 100 born to women who do not have epilepsy. &bull; It is estimated that up to 30-40% of pre-school children whose mothers took valproate during pregnancy may have problems with early childhood development. Children affected can be slow to walk and talk, intellectually less able than other children, and have difficulty with language and memory.<br />&bull; Autistic spectrum disorders are more often diagnosed in children exposed to valproate during pregnancy.<br />&bull; There is some evidence that children exposed to valproate during pregnancy are at increased risk of developing Attention Deficit Hyperactivity Disorder (ADHD).</strong><br />&bull; Before prescribing this medicine to you,<strong> your doctor will have explained what might happen to your baby if you become pregnant while taking valproate.</strong> If you decide later you want to have a baby you must not stop taking your medicine or your method of contraception until you have discussed this with your doctor.<br />&bull; If you are a parent or a caregiver of a female child treated with valproate, you should contact the doctor once your child using valproate has her first period.<br />&bull; Some birth control pills (oestrogen-containing birth control pills) may lower valproate levels in your blood. Make sure you talk to your doctor about the method of birth control that is the most appropriate for you.<br /><strong>Please choose and read the situations which apply to you from the situations described below:</strong><br />o I AM STARTING TREATMENT WITH Depakine<br />o I AM TAKING Depakine AND NOT PLANNING TO HAVE A BABY<br />o I AM TAKING Depakine AND PLANNING TO HAVE A BABY<br />o I AM PREGNANT AND I AM TAKING Depakine<br /><strong>I AM STARTING TREATMENT WITH Depakine</strong><br />If this is the first time you have been prescribed Depakine, your doctor will have explained the risks to an unborn child if you become pregnant. <strong>Once you are able to have a baby, you will need to make sure you use at least 1 effective method of contraception without interruption throughout your treatment with Depakine.</strong> Talk to your doctor, gynaecologist or family planning clinic if you need advice on contraception.<br /><strong>Key messages:</strong><br />&bull; Before starting treatment, your doctor will have to make sure that no treatment other than valproate works for you.<br />&bull; Your doctor will ask you to do a pregnancy test before you start taking this medicine. Pregnancy must be excluded before start of treatment with Depakine with the result of a pregnancy test, confirmed by your doctor.<br />&bull; You must use at least 1 effective method of birth control (preferably an intrauterine device or a contraceptive implant) or 2 effective methods that work differently (for example, the Pill and a condom) during your entire treatment with Depakine.<br />&bull; You must discuss the appropriate methods of birth control with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist for advice on birth control.<br />&bull; You must get regular (at least annual) appointments with a specialist experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull; Tell your doctor you want to have a baby before stopping your birth control.<br />&bull; Schedule an urgent appointment with your specialist experienced in the management of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM TAKING Depakine AND NOT PLANNING TO HAVE A BABY<br />If you are continuing treatment with Depakine but you are not planning to have a baby make sure you are using at least 1 effective method of contraception without interruption during your entire treatment with Depakine. </strong>Talk to your doctor, gynaecologist or family planning clinic if you need advice on contraception.<br /><strong>Key messages:</strong><br />&bull; Your specialist must check regularly (at least once a year) whether any treatment other than valproate works for you.<br />&bull; You must use at least 1 effective method of contraception (preferably an intrauterine device or a contraceptive implant) or 2 effective methods that work differently (for example, the Pill and a condom) during your entire treatment with Depakine.<br />&bull; You must discuss the appropriate methods of birth control with your doctor. Your doctor will give you information on preventing pregnancy, and may refer you to a specialist for advice on birth control.<br />&bull; You must get regular (at least annual) appointments with a specialist experienced in the management of epilepsy. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull; Tell your doctor you want to have a baby before stopping your birth control.<br />&bull; Schedule an urgent appointment with your specialist experienced in the management of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM TAKING Depakine AND PLANNING TO HAVE A BABY</strong><br />Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with development which can be seriously debilitating.<strong> If you are planning to have a baby, first schedule an appointment with your specialist experienced in the management of epilepsy.</strong><br />Do not stop taking Depakine or your contraception until you have discussed this with your doctor. Your doctor will advise you further and refer you to a specialist experienced in the management of epilepsy, so that alternative treatment options can be evaluated early on. Your specialist can put several actions in place so that your pregnancy goes as smoothly as possible and any risks to you and your unborn child are reduced as much as possible.<br />Your specialist will have to do everything possible to stop treatment with Depakine a long time before you become pregnant &ndash; this is to make sure your illness is stable. In exceptional circumstances when this is not possible, see the following paragraph (&ldquo;I AM PREGNANT AND I AM TAKING Depakine&rdquo;).<br />Ask your doctor about taking folic acid when planning to have a baby. Folic acid can lower the general risk of spina bifida and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.<br /><strong>Key messages:</strong><br />&bull; Do not stop taking Depakine unless your doctor tells you to.<br />&bull; Do not stop using your methods of birth control before you have talked to your doctor and worked together on a plan to ensure your condition is controlled and the risks to your baby are reduced.<br />&bull; First schedule an appointment with your doctor. During this visit your doctor will make sure you are well aware and have understood all the risks and advice related to the use of valproate during pregnancy.<br />&bull; Your doctor will try to stop treatment with Depakine a long time before you become pregnant.<br />&bull; Schedule an urgent appointment with your specialist experienced in the management of epilepsy if you are pregnant or think you might be pregnant.<br /><strong>I AM PREGNANT AND I AM TAKING Depakine</strong><br />Babies born to mothers who have been on valproate are at serious risk of birth defects and problems with intellectual, motor and behavioural development which can be seriously debilitating. Do not stop taking Depakine unless your doctor tells you to as your condition may become worse. <strong>Schedule an urgent appointment with your specialist experienced in the management of epilepsy if you are pregnant or think you might be pregnant.</strong><br />&bull; your doctor will advise you further.<br />&bull; your doctor will have to try to stop treatment and evaluate all other treatment options.<br />In the exceptional circumstances when Depakine is the only available treatment option during pregnancy:<br />&bull; your doctor can refer you to a specialist so that you and your partner could receive counselling and support regarding the valproate-exposed pregnancy.<br />&bull; your specialist will try to reduce the prescribed dose.<br />&bull; you will be monitored very closely both for the management of your underlying condition and to check how your unborn child is developing.<br />&bull; Ask your doctor about taking folic acid. Folic acid can lower the general risk of spina bifida and early miscarriage that exists with all pregnancies. However, it is unlikely that it will reduce the risk of birth defects associated with valproate use.<br />&bull; Before the birth: your doctor will prescribe certain vitamins for you so that this medicine does not cause bleeding during the first few days of your baby&rsquo;s life or bone deformities.<br />&bull; After the birth: an injection of vitamin K may also be prescribed for your baby after birth to prevent bleeding.<br />&bull; In the child: inform the doctor(s) monitoring your child that you were treated with valproate during pregnancy. He or she will implement strict monitoring of your child&rsquo;s neurological development in order to provide your child with specialised care as early as possible if necessary.<br /><strong>Key messages:</strong><br />&bull; Schedule an urgent appointment with your specialist experienced in the management of epilepsy if you are pregnant or think you might be pregnant.<br />&bull; Do not stop taking Depakine unless your specialist tells you to.<br />&bull; Your specialist experienced in the treatment of epilepsy must evaluate all of the options for stopping this treatment.<br />&bull; Your specialist must give you complete information about the risks related to the use of Depakine during pregnancy, including the risk of malformations (birth defects) and developmental disorders (intellectual, motor, behavioural) in children.<br />&bull; Make sure you are referred to a specialist for prenatal monitoring in order to detect possible occurrences of malformations.<br />&bull; Inform the doctors who will be monitoring your child that you took Depakine during your pregnancy. They will implement strict monitoring of the child&rsquo;s neurological development.<br /><u><strong>Breast-feeding</strong></u><br />You must not breast-feed during treatment with this medicine unless otherwise indicated by your doctor.<br />Talk to your doctor or pharmacist before taking any medicine.<br /><strong>Driving and using machines</strong><br />Depakine may cause drowsiness, especially if taken in combination with other antiepileptic drugs or medicines that can increase drowsiness.<br />If you experience this effect or if your condition is not under control yet and you continue to have seizures, you must not drive or operate machinery.<br /><strong>Depakine 200 mg/mL oral solution contains sodium.</strong><br />This medicine contains 28 mg sodium (main component of cooking/table salt) per 200 mg sodium valproate. This is equivalent to 1.4% of the recommended maximum daily intake of sodium for an adult. You must take this into account if you are on a salt-free or low-salt diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br /><strong>Instructions for proper use</strong><br />Depakine treatment must be started and supervised by a doctor specialised in the treatment of epilepsy. This treatment must not be prescribed in female children, female adolescents or women able to have a baby unless other treatments are ineffective or not tolerated. If no other treatment is possible, valproate will be prescribed for you and dispensed under very strict conditions (given in the Pregnancy Prevention Programme). A specialist must re-evaluate the need for treatment at least once per year.<br />Always comply with the dose prescribed by your doctor. If you are unsure of anything, talk to your doctor or pharmacist.<br /><u><strong>Dosage</strong></u><br />&bull; The daily dose will be decided on for you and checked by your doctor.<br />&bull; Your doctor should prescribe the dose in milligrams (mg) and not in millilitres (mL). This information is important because the syringe used to draw up the correct dose from the bottle is graduated in milligrams (mg). If your prescription has been written in millilitres (mL), contact your doctor or pharmacist.<br />&bull; The dose is generally divided into:<br />o 2 doses per day in children under 1 year of age.<br />o 3 doses per day in adults and children over 1 year of age.<br />o The dose should preferably be taken during meals.<br /><strong>Patients with renal failure</strong><br />Your doctor may decide to adjust your dose.<br /><u><strong>Method of administration</strong></u><br />&bull; The oral solution should be taken after diluting in a small amount of non-carbonated drink.<br />&bull; The bottle of oral solution is supplied with a syringe for oral administration (pink plunger).<br />&bull; Administer the oral solution only with the syringe supplied in this box.<br />&bull; The graduation marks indicate doses in milligrams (mg) (1 graduation mark every 25 mg, from 50 mg to 400 mg).<br />&bull; The dose to be administered is obtained by drawing the plunger up to the graduation line corresponding to the amount in milligrams (mg) prescribed by your doctor. Read the dose at the top edge of the syringe barrel.<br />&bull; Rinse the syringe after each use.<br /><u><em>Opening the bottle</em></u><br />To open the bottle, push down on the child-safety cap while turning. The bottle must be closed after each use.<br /><img alt="" width="674" height="355" src="data:image/png;base64,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" /><u><strong>Duration of treatment</strong></u><br />Do not stop taking this medicine without your doctor&rsquo;s advice.<br /><strong>If you take more Depakine than you should:</strong><br />Talk to your doctor or go to the emergency room immediately.<br /><strong>If you forget to take Depakine:</strong><br />Do not take a double dose to make up for a forgotten dose.<br /><strong>If you stop taking Depakine:</strong><br />Do not stop taking Depakine without asking your doctor&rsquo;s advice. Treatment must be stopped gradually. If you stop taking Depakine suddenly or before your doctor asks you to, you will be at a higher risk of seizures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Consult your doctor or pharmacist immediately if you experience any of the following effects:</strong><br />&bull; Liver damage (hepatitis) or pancreas damage (pancreatitis), which may be serious and lifethreatening, and that can start suddenly with fatigue, loss of appetite, exhaustion, drowsiness, nausea, vomiting and bowel pain.<br />&bull; Allergic reaction: o sudden swelling of the face and/or neck that can cause difficulty breathing and be lifethreatening (angioedema),<br />o serious allergic reaction (drug hypersensitivity syndrome) including several symptoms such as fever, skin rash, increased size of lymph nodes, liver damage, kidney damage and abnormal blood test results such as an increase in the number of certain white blood cells (eosinophils).<br />&bull; Raised skin rash, sometimes with blisters that can also affect the mouth (erythema multiforme), blisters with detachment of the skin that can rapidly spread to the entire body and be life-threatening (Lyell syndrome, Stevens-Johnson syndrome).<br /><strong>Other possible side effects:</strong><br />&bull; Congenital birth defects and mental and physical development disorders (see &ldquo;Pregnancy, breastfeeding and fertility&rdquo; in section 2).<br /><strong>Very common (may affect more than 1 in 10 people):</strong><br />&bull; nausea,<br />&bull; tremor.<br /><strong>Common (may affect up to 1 in 10 people):</strong><br />&bull; at the beginning of treatment: vomiting, stomach ache, diarrhoea,<br />&bull; weight gain,<br />&bull; headache,<br />&bull; drowsiness,<br />&bull; seizures,<br />&bull; memory disorders,<br />&bull; confusion, aggressiveness, agitation, attention deficit disorders, hallucinations (seeing, hearing or feeling things that are not there),<br />&bull; extrapyramidal disorders (a group of symptoms such as tremor, stiffness of the limbs and difficulty walking)*,<br />&bull; urinary incontinence (unintentional passing of urine),<br />&bull; rapid and uncontrollable eye movements,<br />&bull; hearing loss,<br />&bull; gum disorders (gingival problems), in particular an increase in gum size (gingival hypertrophy),<br />&bull; painful, swollen mouth, mouth ulcers and burning sensation in the mouth (stomatitis), &bull; hair loss,<br />&bull; menstrual problems (irregular menstruation),<br />&bull; bleeding,<br />&bull; nausea or dizziness,<br />&bull; nail and nail bed disorders,<br />&bull; decrease in the number of platelets (thrombocytopenia), decrease in the number of red blood cells (anaemia),<br />&bull; decrease in the amount of sodium in the blood (hyponatremia, syndrome of inappropriate antidiuretic hormone secretion).<br /><strong>Uncommon (may affect up to 1 in 100 people):</strong><br />&bull; impaired alertness that may go as far as transient coma, regressing after the dose is decreased or the treatment stopped,<br />&bull; difficulty coordinating movements,<br />&bull; reversible Parkinsonian syndrome*,<br />&bull; sensation of numbness or prickling in the hands and feet,<br />&bull; abnormal hair texture, change in hair colour, abnormal hair growth,<br />&bull; rash or hives on the skin,<br />&bull; excessive hair growth, particularly in women, virilism, acne (hyperandrogenism),<br />&bull; decreased body temperature (hypothermia),<br />&bull; swelling of the extremities (oedema),<br />&bull; amenorrhea (lack of menstrual period),<br />&bull; worsening and increased frequency of seizures; onset of a different type of seizure,<br />&bull; breathing difficulty and pain, due to inflammation of the protective membranes of the lungs (pleural effusion),<br />&bull; decrease in the numbers of all blood cells: white blood cells, red blood cells and platelets<br />(pancytopenia), decrease in the number of white blood cells (leukopenia),<br />&bull; cases of bone disorders have been reported, such as the bones becoming more fragile (osteopenia), a decrease in bone mass (osteoporosis) and fractures. Consult your doctor or pharmacist if you are receiving long-term treatment with an antiepileptic drug, if you have a history of osteoporosis or if you are taking corticosteroids,<br />&bull; blood vessel inflammation.<br /><strong>Rare (may affect up to 1 in 1 000 people):</strong><br />&bull; difficulty retaining urine (enuresis),<br />&bull; male infertility, generally reversible after discontinuing treatment for at least 3 months and possibly reversible after dose reduction. Do not stop your treatment without first talking to your doctor,<br />&bull; abnormal functioning of the ovaries (polycystic ovary syndrome),<br />&bull; behavioural disturbances, increased psychomotor activity, learning disabilities,<br />&bull; auto-immune reaction with painful joints, skin rash and fever (systemic lupus erythematosus),<br />&bull; decreased thyroid gland activity (hypothyroidism),<br />&bull; muscle pain, muscle weakness that may be serious (rhabdomyolysis),<br />&bull; obesity,<br />&bull; kidney damage (kidney failure, tubulointerstitial nephritis, Fanconi syndrome),<br />&bull; increase in the size of red blood cells (macrocytosis), major decrease in the number of white blood cells (agranulocytosis),<br />&bull; reduced production of blood cells (bone marrow aplasia), blood cell production abnormality (myelodysplasia),<br />&bull; decrease in coagulation factors, abnormal blood coagulation test results (increase in INR, increase in activated partial thromboplastin time),<br />&bull; decrease in the amount of vitamin B8 (biotin)/biotinidase,<br />&bull; increase in the amount of ammonium in the blood,<br />&bull; double vision,<br />&bull; memory and mental capacity disorders that appear gradually (cognitive disorders, dementia)* and regress a few weeks to a few months after stopping treatment.<br />Do not stop your treatment without first talking to your doctor.<br />*These symptoms can be associated with brain imaging signs (cerebral atrophy).<br /><strong>Additional side effects in children</strong><br />Some side effects of valproate occur more frequently in children or are more severe compared to adults. These include liver damage, inflammation of the pancreas (pancreatitis), aggression, agitation, disturbance in attention, abnormal behaviour, hyperactivity and learning disorders.<br /><strong>Reporting of side effects<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is:<br />Sodium valproate .......................................................................................................................... 20.00 g<br />For 100 mL.<br />1 mL of solution is equivalent to 200 mg of sodium valproate.<br />&bull; The other ingredients are:<br />Urea, 30% sodium hydroxide solution and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is supplied as an oral solution. 40 mL bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder<br />Sanofi-Aventis france</strong><br />82, avenue Raspail<br />94250 Gentilly, France<br /><br /><strong>Manufacturer<br />Unither Liquid Manufacturing</strong><br />1-3, allee de la Neste 31770 Colomiers, France or<br /><strong>Sanofi Winthrop Industrie</strong><br />30-36, avenue Gustave Eiffel 37100 Tours, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                30-Jan-2025
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">.N03AG01 :ATC المجموعة الدوائية العلاجية: مضادات الصرع، رمز<br />ينتمي ديباين إلى فئة من الأدوية تسُمّى مضادات الصرع.<br />يسُتعمل هذا الدواء لمعالجة الأشكال المختلفة من نوبات الصرع لدى البالغين والأطفال. يسُتعمل لدى الأطفال<br />كذلك للعلاج الوقائي من الاختلاجات المتعلّقة بالحمى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا ينبغي أخذ ديباكين 200 ملغ/مل، محلول للشرب :</strong></p><ul><li>&bull; إذا كنتِ حاملا إلا إذا لم يكن أيّ علاج آخر للصّرع فعّالا بالنسبة إليك (راجعي أدناه &quot;الحمل والإرضاع</li><li>والخصوبة - نصائح مهمّة موجّهة إلى النساء&quot;)،</li><li>&bull; إذا كنت امرأة في سنّ الإنجاب، إلا إذا لم يكن أيّ علاج آخر للصّرع فعاّلا بالنسبة إليك وكنت قادرة على التقيدّ</li><li>بكلّ إجراءات خطّة الوقاية لتجنّب الحمل (راجعي أدناه &quot;الحمل والإرضاع والخصوبة - نصائح مهمّة موجّهة إلى</li><li>النساء&quot;)،</li><li>&bull; إذا كنت تعاني من حساسية ضد المادة الفاعلة (فالبروات الصوديوم) أو ضدّ أحد المركّبات الأخرى في هذا الدواء</li><li>،( (المذكورة في القسم 6</li><li>&bull; إذا كنت تعاني من حساسيةّ ضد دواء من فئة الفالبروات (ديفالبروات، فالبروميد)،</li><li>&bull; إذا كنت تعاني من مرض في الكبد (التهاب الكبد الحاد أو المزمن)،</li><li>&bull; إذا أصبت أنت أو فرد من عائلتك بالتهاب خطير في الكبد، لا سيمّا إذا كان مرتبطًا بأخذ دواء،</li><li>&bull; إذا كنت تعاني من البرفيريةّ الكبديةّ (وهو مرض وراثي في الكبد)،</li><li>&bull; إذا كنت تعاني من مشكلة وراثيةّ تسببّ اضطراباً في الميتوكوندريا (مثلا متلازمة ألبرس-هوتنلوكر)،</li><li>&bull; إذا كنت تعاني من اضطراب معروف في الأيض، مثل اضطراب في دورة اليوريا (راجع فقرة &quot;تحذيرات واحتياطات&quot;)،</li><li>&bull; إذا كنت تتناول في الوقت نفسه:</li><li>نبتة سانت جون (وهي نبتة تسُتعمل لعلاج الاكتئاب).&nbsp;</li></ul><p><strong>تحذيرات واحتياطات</strong><br />قد يؤدي هذا الدواء, في حالات نادرة جدًا , إلى اصابة الكبد (التهاب الكبد), أو البنكرياس (التهاب البنكرياس), وذلك قد يكون خطيرًا ويهدد حياتك.&nbsp;<br />سوف يصف لك طبيبك فحوصات دم لكي يراقب بانتظام وظيفة الكبد لديك، بخاصة في الأشهر الستة الأولى من العلاج.<br />ابلغ الطبيب على الفور اذا لاحظت ايًا من الاعراض التالية :<br />&bull; تعب مفاجئ، فقدان الشهیة، إرهاق، نعاس، تورّم الساقين، توعّك عام ،<br />&bull; تقيؤّ متكرر، غثيان، ألم في البطن والمعدة، تلوّن البشرة أو العينين باللون الأصفر (يرقان)،<br />&bull; إعادة ظهور نوبات الصرع بالرغم من اتبّاع العلاج بصورة صحيحة.<br />&bull; قبل أخذ هذا الدواء، أعلم طبهبك إذا كنت تعاني من مرض كلوي (قصور كلوي)، أو من الذئبة الحمامية الجهازية<br />(مرض نادر) أو من نقص الانزيمات الوراثي، بخاصة نقص في انزيم دورة اليوريا ممايمكن أن يسببّ زيادة كميةّ<br />الأمونيا في الدم أو مشكلة وراثيةّ مسؤولة عن اضطراب في الميتوكوندريا (بما في ذلك في أسرتك).<br />&bull; إذا كنت ستخضع لعملية جراحية، يجب عليك إبلاغ الطاقم الطبي بأنّك تأخذ هذا الدواء.<br />&bull; في بداية العلاج، سوف يتأكد الطبيب من أنك لست حاملاً ومن أنّك تستعملين وسیلة لمنع الحمل (راجعي فقرة<br />&quot;الحمل&quot;).<br />&bull; كما مع مضادات الصّرع الأخرى، وبعد أخذ هذا الدواء، يمكن أن تتفاقم نوبات الصّرع أو أن تحدث أكثر أو يمكن أن<br />تظهر نوبات من نوع آخر.<br />&bull; يمكن أن يسبّب هذا الدواء زيادة في الوزن. سوف ينصحك طبيبك باتباع بعض إجراءات الحمية وسوف يراقب<br />وزنك.<br />&bull; لوحظ أيضًا ظهور أفكار مدمّرة للذات أو أفكار انتحارية لدى عدد قليل من المرضى المعالجين بواسطة مضادات<br />الصرع مثل ديباكين. فإذا راودتك أفكار من هذا النوع، اتصل بطبيبك فورًا.<br />&bull; إذا كنت تعاني من نقص في الكارنيتين بالميتويل ترانسفيراز من النوع 2 (مرض أيضيّ وراثيّ)، يكون خطر حصول<br />مشاكل عضليةّ خطيرة (انحلال الربيدات) مع هذا الدواء أكبر.<br />&bull; في حالة ظھور أعراض مثل الرجفة أو تیبسّ الأعضاء وصعوبات في السیر (اضطرابات خارج الھرمیةّ) أو<br />اضطرابات في الذاكرة وفي القدرات الذھنیّة، أعلم طبیبك. یجب البحث عن مرض كامن أو عن مسؤولیّة دیباكین<br />200 ملغ/مل، محلول للشرب. قد یكون من الضروريّ إیقاف العلاج.<br />أعلم طبیبك إذا كان طفلك یأخذ علاجًا آخر مضادًا للصرع أو إذا كان یعاني من مرض عصبيّ أو أیضيّ آخر أ و من أشكال<br />حادة من الصّرع.<br />أدویة أخرى ودیباكین 200 ملغ/مل، محلول للشرب<br />قد تؤثرّ بعض الأدویة على مفعول فالبروات والعكس صحیح.<br />لا ینبغي علیك مطلقاً أخذ ھذا الدواء إذا كنت تأخذ الدواء التالي:<br />&bull; نبتة سانت جون (دواء نباتيّ الأصل یسُتعمل لعلاج الاكتئاب).<br />لا تأخذ ھذا الدواء، إلّا إذا قال لك الطّبیب أو الصیدليّ غیر ذلك، إذا كنت تأخذ، أو أخذت مؤخّرًا أو قد تأخذ الأدویة التالیة:<br />&bull; لاموتریجین (دواء آخر یسُتعمل لعلاج نوبات الصرع)؛<br />&bull; أدویة بینیم (الكاربابینیم) (مضادات حیویةّ مستعملة لعلاج حالات العدوى البكتیریةّ).<br />أعلم طبیبك إذا كنت تأخذ:<br />&bull; الأدویة التي تحتوي على الأسیتازولامید (أدویة تسُتعمل لتخفیض ضغط العین أو مستویات ثاني أكسید الكربون في<br />الدم)؛<br />&bull; المضادات الحیویّة (أدویة تحتوي على أزتریونام أو ریفامبیسین)؛<br />&bull; أدویة أخرى مضادة للصرع (أدویة تحتوي على كاربامازیبین، فلبامات، فینیتوین، فوسفینیتوین، بریمیدون،<br />فینوباربیتال، روفینامید، توبیرامات أو زونیسامید)؛<br />&bull; النیمودیبین: یمكن أن یزید دیباكین تأثیرات النیمودیبین (دواء یسُتعمل للوقایة من المضاعفات التي یمكن أن تحصل بعد<br />نزیف على مستوى الدماغ)؛<br />&bull; أدویة تحتوي على الإستروجینات (بما فیھا بعض حبوب منع الحمل)؛<br />&bull; بروبوفول (دواء مخدرّ)؛<br />&bull; الأدویة التي تحتوي على زیدوفودین (أدویة تسُتعمل لعلاج عدوى فیروس نقص المناعة البشریةّ)؛<br />&bull; الأدویة التي تحتوي على اللیثیوم (أدویة تسُتعمل لعلاج اضطرابات المزاج)؛<br />&bull; الأدویة التي تحتوي على المیتامیزول (أدویة تسُتعمل لعلاج الألم والحمى)؛<br />&bull; السالیسیلات (بما فیھا الأسبیرین)؛<br />&bull; الكانابیدیول (یسُتعمل لعلاج الصرع وأمراض أخرى).<br />بخاصة لدى الأطفال ما دون الثالثة من العمر، یجب تفادي إعطاء أدویة تحتوي على السالیسیلات (بما فیھا الأسبیرین)<br />خلال مدّة العلاج.<br />أعلم الطبیب أو الصیدلي إذا كنت تأخذ حالیًا أو أخذت مؤخّرًا أو قد تأخذ أيّ أدویة أخرى.<br />دیباكین 200 ملغ/مل، محلول للشرب مع الطعام والشراب والكحول<br />لا ینُصح باستھلاك المشروبات الكحولیةّ خلال مدةّ العلاج بدیباكین.<br />الحمل والإرضاع والخصوبة&nbsp;<br />الحمل<br />نصائح مھمّة موجّھة إلى النساء<br />یشكّل الفالبروات خطرًا على الجنین إذا أُخذ أثناء الحمل.<br />وبالتالي:<br />&bull; إذا كنتِ فتاة أو مراھقة أو امرأة في سنّ الإنجاب، لا یمكن أن یصف لك طبیبك الأخصّائي الفالبروات، إلا في حالة<br />عدم فعالیّة العلاجات الأخرى أو عدم تحمّلھا. إذا لم یكن أيّ علاج آخر ممكنًا، سوف یوصف لك الفالبروات ویُصرف<br />وفقًا لشروط صارمة جدًا موصوفة أدناه.<br />&bull; تأكّدي من أنّك ق رأت كتیبّ المعلومات الخاص بالمریضة الذي یزوّدك بھ طبیبك الأخصّائي. سوف یناقش طبیبك معك<br />النموذج السنوي للموافقة على الرعایة وسوف یطلب منك توقیعھ والاحتفاظ بھ. یجب أن تقدّمیھ إلى الصیدليّ عند<br />كلّ استلام للدواء وكذلك وصفة الأخصّائي. یؤكّد ھذا النموذج أنّھ تمّ شرح المخاطر لك جیّدًا وأن ك توافقین على التقیدّ<br />بالشروط أدناه. علاوة على ذلك، سوف یسلمّك الصیدليّ بطاقة مریضة تذكّرك أیضًا بالمخاطر المرتبطة بأخذ<br />الفالبروات خلال فترة الحمل.<br />لا ینبغي علیك أخذ دیباكین:<br />&bull; إذا كنتِ حاملا إلا إذا لم یكن أيّ علاج آخر للصّرع فعاّلا بالنسبة إلیك،<br />&bull; إذا كنت امرأة في سنّ الإنجاب، إلا إذا لم یكن أيّ علاج آخر للصّرع فعاّلا بالنسبة إلیك وكنت قادرة على التقیدّ<br />بكلّ إجراءات خطّة الوقایة لتجنّب الحمل.<br />المخاطر المرتبطة بأخذ الفالبروات خلال فترة الحمل<br />&bull; توجّھي إلى طبیبك الأخصّائيّ على الفور إذا كنت تنوین الحمل أو إذا كنت حاملاً أو إذا كنت تعتقدین نفسك حاملاً.<br />&bull; یعرّض الفالبروات الجنین للخطر إذا أُخذ خلال فترة الحمل. كلّما كانت الجرعة مرتفعة، كلّما كانت المخاطر كبیرة؛<br />ولكن كلّ الجرعات تُعرّض لھذا الخطر، بما في ذلك حین یسُتعمل الفالبروات بالاشتراك مع أدویة أخرى لعلاج الصرع .<br />&bull; إذا أخذت امرأة حامل الفالبروات، فإنّھ یسبّب تشوّھات خلقیةّ خطیرة وقد یؤذي التقدمّ (الذھنيّ والحركيّ والسلوكيّ) لدى<br />الطفل خلال فترة نموّه.<br />&bull; تتضمّن التشوّھات الخلقیةّ المبلغّ عنھا بصورة أكثر شیوعًا السنسنة المشقوقة (تشوّه عظمي في العمود الفقري)، وتشوّھات<br />في الوجھ وفي الشفة العلیا والحنك والجمجمة والقلب والكلیتین والمسالك البولیّة والأعضاء التناسلیّة والأعضاء أیضًا<br />وعدّة تشوّھات ذات الصلة تؤثّر على أعضاء وأجزاء مختلفة من الجسم. قد تؤدّي التشوّھات الخلقیّة إلى إعاقات قد تكون<br />حادّة.<br />&bull; تمّت الإفادة لدى الأطفال المعرّضین للفالبروات خلال فترة الحمل عن مشاكل في السمع أو الصمم.<br />&bull; تمّت الإفادة لدى الأطفال المعرّضین للفالبروات خلال فترة الحمل عن تشوّھات في العینیْن بالاشتراك مع تشوّھات خلقیةّ<br />أخرى. یمكن أن تؤثّر ھذه التشوّھات في العینیْن على البصر .<br />ا أعلى من 􀌒 &bull; إذا كنت تأخذین الفالبروات خلال فترة الحمل، یكون خطر إنجابك طفلاً مصابًا بتشوّھات تتطلّب علاجًا طبی<br />الخطر الذي تواجھھ النساء الأخریات. بما أنّ الفالبروات یُستعمل منذ سنوات كثیرة، أثُبت أنّ ما یقارب 11 طفل من&nbsp;أصل 100 من الأطفال المولودین من أمّھات معالجات بالفالبروات یصُابون بتشوّھات، مقابل 2 إلى 3 أطفال من أصل<br />100 من الأطفال بین عامة السكّان.<br />&bull;<br />یقُدّر أنّ لغایة 30 إلى 40 % من الأطفال في مرحلة ما قبل المدرسة الذین أخذت أمّھاتھم الفالبروات خلال فترة الحمل،<br />یعانون من مشاكل نموّ في مرحلة طفولتھم المبكرة. الأطفال المعنیوّن یتأخّرون في السّیر و/أو في الكلام و/أو تكون<br />قدراتھم الذھنیّة أضعف من قدرات الأطفال الآخرین، و/أو یواجھون صعوبات في الكلام و/أو في الذاكرة.<br />&bull; یتمّ تشخیص اضطرابات طیف التوحّد أكثر لدى الأطفال المعرّضین للفالبروات خلال فترة الحمل.<br />&bull; تشیر بیانات إلى أنّ خطر الإصابة باضطراب نقص الانتباه/فرط النشاط أعلى لدى الأطفال المعرّضین للفالبروات خلال<br />فترة الحمل.<br />&bull; قبل وصف ھذا الدواء لك، یجب أن یكون طبیبك قد شرح لكِ المخاطر المحتملة على طفلك في حالة الحمل خلال فترة<br />أخذ الفالبروات. وفي حال قررت الحمل في فترة لاحقة، لا ینبغي علیك إیقاف علاجك أو وسیلة منع الحمل التي تعتمدینھا<br />من دون أن تكوني تحدّثت عن الأمر مع طبیبك.<br />&bull; إذا كنت والدًا/والدة فتاة أو كنت تعتني/تعتنین بفتاة تُعالج بالفالبروات، یجب علیك الاتصال بالطبیب الأخصّائي ما أن<br />تأتي دورتھا الشھریةّ الأولى.<br />&bull; یمكن أن تخفّض بعض حبوب منع الحمل (حبوب تحتوي على الإستروجینات) معدّلات الفالبروات في دمك. یجب التحدّث<br />إلى الطبیب لتحدید وسیلة منع الحمل المناسبة لك.<br />الرجاء اختیار الوضع الذي یناسب حالتك من القائمة أدناه وقراءة الفقرة المناسبة:<br />أبدأ العلاج بدیباكین o<br />آخذ دیباكین ولا أنوي الحمل o<br />آخذ دیباكین وأنوي الحمل o<br />أنا حامل وآخذ دیباكین o<br />أبدأ العلاج بدیباكین<br />إذا كان دیباكین یوصف لكِ للمرّة الأولى، یجب أن یكون طبیبك الأخصّائي قد شرح لكِ المخاطر التي تواجھ الجنین في حالة<br />الحمل. إذا كنتِ في سنّ الإنجاب، یجب أن تستعملي وسیلة منع حمل فعّالة واحدة على الأقلّ بدون توقّف طیلة مدّة علاجك<br />بدیباكین. للحصول على معلومات حول منع الحمل، استشیري الطبیب العام أو الطبیب النسائي أو مركز تخطیط عائلي.<br />رسائل رئیسیةّ:<br />&bull; قبل البدء بالعلاج، سوف یتأكّد الطبیب من عدم وجود أيّ علاج غیر الفالبروات ممكن لك.<br />&bull; سوف یطلب منك طبیبك إجراء فحص حمل قبل أن تبدأي بأخذ ھذا الدواء. یجب أن تؤكّد النتیجة التي یراھا طبیبك أنّك<br />لست حاملا عندما تبدأین علاجك بدیباكین.<br />&bull; یجب علیك أن تستعملي وسیلة منع حمل فعّالة واحدة على الأقلّ (یُفضّل استعمال جھاز داخل الرحم أو وسیلة منع حمل<br />عن طریق الزرع) أو وسیلتین فعاّلتین تعملان بطریقة مختلفة (مثلا حبةّ منع حمل ھورمونیةّ وواقِ ذكريّ) طیلة مدةّ<br />علاجك بدیباكین.<br />&bull; یجب علیك أن تناقشي وسائل منع حمل مناسبة مع طبیبك. سوف یزوّدك طبیبك بمعلومات حول منع الحمل ویمكن أن<br />یوجّھك إلى أخصّائيّ سوف یعطیك نصائح تتعلّق بمنع الحمل.<br />&bull; یجب علیك أن تستشیري بشكل منتظم (مرّة واحدة في السنة على الأقلّ) طبیبًا أخصّائیًا لدیھ خبرة في علاج الصرع. عند<br />ھذه الاستشارة، سوف یتأكّد طبیبك من أنكّ تدركین المخاطر ومن أنكّ فھمت المعلومات المرتبطة بمخاطر أخذ الفالبروات<br />خلال فترة الحمل.<br />&bull; إذا كنت ترغبین في الحمل، تحدثّي إلى طبیبك الأخصّائيّ قبل إیقا ف وسیلة منع الحمل التي تستعملینھا.<br />&bull; إذا كنتِ حاملا أو كنت تعتقدین نفسك كذلك، خذي موعدًا على الفور مع طبیبك الأخصّائيّ الذي لدیھ خبرة في علاج<br />الصرع.<br />آخذ دیباكین ولا أنوي الحمل<br />إذا كنت تواصلین العلاج بدیباكین وكنت لا تنوین الحمل، تأكّدي من استعمال وسیلة منع حمل واحدة على الأقلّ بدون توقّف<br />طیلة مدّة علاجك ب دیباكین. للحصول على معلومات حول منع الحمل، استشیري الطبیب العام أو الطبیب النسائي أو مركز<br />تخطیط عائلي.<br />رسائل رئیسیةّ:<br />&bull; سوف یتأكّد الطبیب الأخصّائيّ بشكل منتظم (مرّة واحدة في السنة على الأقلّ) من عدم وجود أيّ علاج غیر الفالبروات<br />ممكن لك.<br />&bull; یجب علیك أن تستعملي وسیلة منع حمل فعّالة واحدة على الأقلّ (یُفضّل استعمال جھاز داخل الرحم أو وسیلة منع حمل<br />عن طریق الزرع) أو وسیلتین فعاّلتین تعملان بطریقة مختلفة (مثلا حبةّ منع حمل ھورمونیةّ وواقِ ذكريّ) طیلة مدةّ<br />علاجك بدیباكین.<br />&bull; یجب علیك أن تناقشي وسائل منع حمل مناسبة مع طبیبك. سوف یزوّدك طبیبك بمعلومات حول منع الحمل ویمكن أن<br />یوجّھك إلى أخصّائيّ سوف یعطیك نصائح تتعلقّ بمنع الحمل.<br />&bull; یجب علیك أن تستشیري بشكل منتظم (مرّة واحدة في السنة على الأقلّ) طبیبًا أخصّائیًا لدیھ خبرة في علاج الصرع. عند<br />ھذه الاستشارة، سوف یتأكّد طبیبك من أنكّ تدركین المخاطر ومن أنكّ فھمت المعلومات المرتبطة بمخاطر أخذ الفالبروات<br />خلال فترة الحمل.<br />&bull; إذا كنت ترغبین في الحمل، تحدثّي إلى طبیبك الأخصّائيّ قبل إیقا ف وسیلة منع الحمل التي تستعملینھا.<br />&bull; إذا كنتِ حاملاً أو كنت تعتقدین نفسك كذلك، خذي موعدًا على الفور مع طبیبك الأخصّائيّ الذي لدیھ خبرة في علاج<br />الصرع.<br />آخذ دیباكین وأنوي الحمل<br />یواجھ الأطفال المولودون من أمّھات معالجات بالفالبروات خطرًا كبیرًا للإصابة بتشوّھات وباضطرابات في النموّ یمكن أن<br />تسبّب لھم إعاقات كبیرة. إذا كنت تنوین الحمل، خذي أوّلا موعدًا مع طبیبك الأخصّائي الذي لدیھ خبرة في علاج الصّرع.<br />لا تتوق فّي عن أخذ دیباكین أو استعمال وسیلة منع الحمل قبل أن تتحدّثي بالأمر مع طبیبك. سوف یزوّدك طبیبك بنصائح<br />إضافیّة وسوف یوجّھك إلى طبیب أخصّائيّ لدیھ خبرة في علاج الصّرع لكي یتمكّن من أن یقیّم في الوقت المناسب العلاجات<br />الممكنة الأخرى. یمكن أن یتخذ الطبیب الأخصّائيّ تدابیر مختلفة لكي یسیر حملك على ما یرام ولكي تكون المخاطر علیك<br />وعلى طفلك محدودة قدر الإمكان.<br />یجب على طبیبك الأخصّائيّ بذل جھده لإیقاف ھذا العلاج بدیباكین، قبل وقت طویل من حملك بغیة التأكّد من استقرار مرضك.<br />للحالات الاستثنائیةّ التي یكون فیھا ھذا الأمر مستحیلا ،ً راجعي الفقرة التالیة (&quot;أنا حامل وآخذ دیباكین&quot;).<br />إذا كنتِ تنوین الحمل، اسألي طبیبك الأخصّائي حول أخذ حمض الفولیك. فأخذ مكمّلات حمض الفولیك، یمكن أن یخفّض<br />خطر السنسنة المشقوقة والإجھاض المبكر الذي یمكن أن یحصل مع كلّ حمل. ولكن من غیر المرجّح أن یخفّض خطر<br />التشوّھات المرتبطة باستعمال الفالبروات.<br />رسائل رئیسیةّ:<br />&bull; لا تتوقّفي عن أخذ دیباكین بدون أن یكون طبیبك قد طلب ذلك منك.<br />&bull; لا تتوقفّي عن استعمال وسائل منع الحمل التي تستعملینھا قبل أن تناقشي الأمر مع طبیبك الأخصّائي وقبل أن تتفقا معاً<br />على علاج لكيّ تتأكّدا من أن مرضك تحت السیطرة وأنّ المخاطر على طفلك محدودة.<br />&bull; خذي أوّلاً موعدًا مع طبیبك الأخصّائي. عند ھذه الاستشارة، سوف یتأكّد طبیبك من أنكّ تدركین المخاطر ومن أنكّ فھمت<br />المعلومات المرتبطة بمخاطر أخذ الفالبروات خلال فترة الحمل.<br />&bull; یجب على طبیبك الأخصّائيّ بذل جھده لإیقاف ھذا العلاج بدیباكین، قبل وقت طویل من حملك.<br />&bull; إذا كنتِ حاملاً أو كنت تعتقدین نفسك كذلك، خذي موعدًا على الفور مع طبیبك الأخصّائيّ الذي لدیھ خبرة في علاج<br />الصرع.<br />أنا حامل وآخذ دیباكین<br />یواجھ الأطفال المولودون من أمّھات معالجات بالفالبروات خطرًا كبیرًا للإصابة بتشوّھات وباضطرابات في النمو الذھنيّ<br />والحركيّ یمكن أن تسبّب لھم إعاقات كبیرة. لا تتوقّفي عن أخذ دیباكین من دون أن یكون طبیبك طلب ذلك؛ فھذا یمكن أن<br />یزید مرضك سوءًا. إذا كنتِ حاملا أو كنت تعتقدین نفسك كذلك، خذي موعدًا على الفور مع طبیبك الأخصّائيّ الذي لدیھ<br />خبرة في علاج الصرع.<br />&bull; سوف یعطیك طبیبك نصائح إضافیّة.<br />&bull; یجب أن یبذل طبیبك جھده لإیقاف العلاج وتقییم مجموع العلاجات الأخرى المحتملة.<br />في حالات استثنائیةّ، إذا كان دیباكین الخیار العلاجيّ المتاح الوحید خلال فترة حملك:<br />&bull; یمكن أن یوجّھك طبیبك إلى أخصّائيّ لكي تتلقیا أنت وشریكك المساعدة ونصائح تتعلقّ بالحمل مع أخذ فالبروات.<br />&bull; سوف یحاول طبیبك الأخصّائيّ تخفیض الجرعة الموصوفة.<br />&bull; سوف تتمّ متابعتك عن كثب، لعلاج مرضك ولمراقبة نموّ جنینك على حد سواء.<br />&bull; اسألي طبیبك حول أخذ حمض الفولیك. فأخذ حمض الفولیك یمكن أن یخفّض خطر السنسنة المشقوقة والإجھاض المبكر<br />الذي یمكن أن یحصل مع كلّ حمل. ولكن من غیر المرجّح أن یخفّض خطر التشوّھات المرتبطة باستعمال الفالبروات.<br />&bull; قبل الولادة: سوف یصف لك طبیبك بعض الفیتامینات لتفادي أن یسببّ ھذا الدواء نزیفاً خلال الأیاّم الأولى من الحیاة أو<br />اضطرابات في تشكّل عظم طفلك.<br />&bull; بعد الولادة: یمكن أیضًا وصف حقنة فیتامین ك لطفلك، عند الولادة، لتفادي النزیف.<br />&bull; لدى الطفل: أعلمي الطبیب (الأطبّاء) الذي (الذین) سوف یتابع (یتابعون) طفلك بأنّك عولجت بالفالبروات خلال حملك.<br />سوف یُجري (یُجرون) رصدًا دقیقًا للتطوّر العصبيّ لطفلك بغیة تزویده برعایة متخصصة في أقرب وقت ممكن، عند<br />الضرورة.<br /><strong>رسائل رئیسیةّ:</strong><br />&bull; إذا كنتِ حاملاً أو كنت تعتقدین نفسك حاملاً، خذي على الفور موعدًا مع طبیبك الأخصّائي الذي لدیھ خبرة في معالجة<br />الصرع.<br />&bull; لا تتوقّفي عن أخذ دیباكین من دون أن یكون طبیبك الأخصّائي طلب ذلك.<br />&bull; یجب على طبیبك الأخصّائي الذي لدیھ خبرة في علاج الصرع تقییم كلّ الإمكانیاّت لإیقاف ھذا العلاج.<br />&bull; یجب على طبیبك الأخصّائي تزویدك بالمعلومات الكاملة حول المخاطر المرتبطة بأخذ دیباكین أثناء الحمل، بخاصة<br />مخاطر حصول تشوّھات (تشوّھات خلقیّة) واضطرابات النموّ (الذھنيّ والحركيّ والسلوكيّ) لدى الأطفال.<br />&bull; تأكّدي من أنھّ تمّ توجیھك نحو طبیب متخصّص في المراقبة قبل الولادة بھدف كشف أيّ تشوّھات محتملة.<br />&bull; أعلمي الأطبّاء الذین سوف یتابعون طفلك بأنّك أخذت دیباكین خلال حملك. سوف یُجرون رصدًا دقیقًا للتطوّر العصبيّ<br />لطفلك.<br /><u><strong>الإرضاع</strong></u><br />لا ینبغي علیك أن ترُضعي إذا كنتِ تأخذین ھذا الدواء إلا إذا أشار الطبیب إلى خلاف ذلك.<br />استشیري الطبیب أو الصیدلي قبل أخذ أيّ دواء.<br /><strong>قیادة السیارات واستعمال الآلات</strong><br />یمكن أن یسببّ دیباكین النعاس بخاصة إذا كنت تأخذ في الوقت ذاتھ مضاد اختلاج آخر أو دواء یمكن أن یزید النعاس.<br />إذا تعرّضت لھذا التأثیر أو إذا لم یكن مرضك تحت السیطرة بعد وكنت لا تزال تُصاب بنوبات صرع، لا ینبغي علیك قیادة<br />سیاّرة أو استعمال آلة.<br /><strong>یحتوي دیباكین 200 ملغ/مل، محلول للشرب على الصودیوم.</strong><br />یحتوي ھذا الدواء على 28 ملغ من الصودیوم (المكوّن الرئیسي في ملح الطعام) في 200 ملغ من فالبروات الصودیوم مما<br />یعادل 1.4 % من الكمیّة الغذائیّة الیومیّة القصوى من الصودیوم الموصى بھا للبالغین. یجب أخذ ھذا المحتوى بعین الاعتبار<br />إذا كنت تتبع نظامًا غذائیًا من دون ملح أو قلیل الملح.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائمًا على أخذ ھذا الدواء بالتقیّد تمامًا بتعلیمات طبیبك أو الصیدليّ. تحقق من الطبیب أو الصیدلي في حال الشكّ.<br />تعلیمات لاستعمال جیدّ<br />یجب أن یبدأ العلاج بدیباكین ویراقبھ طبیب مختصّ في علاج الصرع. لا ینبغي وصف العلاج للفتیات أو المراھقات أو النساء<br />في سنّ الإنجاب إلاّ في حالة عدم فعالیّة أو عدم تحمّل العلاجات الأخرى. إذا لم یكن علاج آخر ممكنًا، سوف یتمّ وصف<br />الفالبروات لك وصرفھ وفقًا لشروط صارمة جدًا (مذكورة في برنامج الوقایة من الحمل). یجب على أخصّائيّ أن یعید تقییم<br />ضرورة العلاج مرّة واحدة في السنة على الأقلّ.<br />تقیّد دائمًا بالجرعة التي یصفھا طبیبك. في حال الشكّ، استشر الطبیب أو الصیدلي.<br />مقدار الجرعة<br />&bull; یحددّ طبیبك الجرعة الیومیةّ التي یجب استعمالھا ویراقبھا فردیاً.<br />&bull; یجب أن یصف لك طبیبك جرعة بالمیلیغرام (ملغ) ولیس بالمیلیلتر (مل). ھذه المعلومة مھمّة لأنّ المحقنة المستعملة<br />لأخذ الجرعة المناسبة في القارورة مدرّجة بالمیلیغرام (ملغ). إذا حُررت وصفتك بالمیلیلتر (مل)، اتصل بالطبیب أو<br />بالصیدليّ .<br />&bull; عادة تقُسم الجرعة إلى :<br />جرعتین في الیوم للأطفال ما دون السنة من العمر. o<br />3 جرعات في الیوم للبالغین والأطفال فوق السنة من العمر. o<br />یُفضّل أخذ الجرعة مع الطعام. o<br />المرضى الذین یعانون من قصور كلويّ<br />قد یقرّر طبیبك تعدیل جرعتك.<br />طریقة الاستعمال<br />&bull; یجب بلع محلول الشرب بعد تخفیفھ في كمیّة صغیرة من مشروب غیر غازيّ.<br />&bull; تأتي مع قارورة محلول الشرب محقنة للإعطاء عن طریق الفم (مكبس زھريّ اللون).<br />&bull; یجب إعطاء محلول الشرب فقط بواسطة المحقنة الموجودة في ھذه العلبة.<br />&bull; تشیر الخطوط المدرّجة إلى الدرجات بالمللیغرام (علامة مدرّجة كلّ 25 ملغ، 50 ملغ إلى 400 ملغ).<br />&bull; یتمّ الحصول على الجرعة الواجب إعطاؤھا بسحب المكبس حتىّ العلامة المدرّجة التي تطابق الكمیّة بالمللیغرام (ملغ)<br />التي وصفھا طبیبك. یجب قراءة الجرعة عند مستوى طوق المحقنة.<br />&bull; یجب غسل المحقنة بعد كلّ استعمال.<br />فتح القارورة<br />لفتح القارورة، یجب إدارة الغطاء المزوّد بنظام سلامة للأطفال مع الضغط علیھ. یجب إعادة إغلاق القارورة بعد كلّ استعمال.<br />لفتح القارورة:<br />1) إضغط على غطاء السلامة<br />2) وأدر في الوقت ذاته<br /><img alt="" width="674" height="355" src="data:image/png;base64,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" />1) قم بالتعبئة 2) اضبط الجرعه&nbsp;3) أفرغ<br />استعمال المحقنة للإعطاء عن طریق الفم<br /><u><strong>مدّة العلاج</strong></u><br />لا تتوقف عن أخذ ھذا الدواء من دون استشارة الطبیب أوّلاً.<br />إذا أخذت جرعة مفرطة من دیباكین:<br />اتصل بالطبیب أو بقسم الطوارئ الطبیّة على الفور.<br />إذا نسیت أخذ دیباكین:<br />لا تأخذ جرعة مضاعفة للتعویض عن الجرعة التي نسیت أخذھا .<br />إذا توقّفت عن أخذ دیباكی ن:<br />لا تتوقّف عن أخذ دیباكین بدون استشارة طبیبك أوّلاً. یجب إیقاف العلاج تدریجیًا. إذا توقّفت فجأة عن أخذ دیباكی ن أو قبل أن<br />یطلب طبیبك منك ذلك، سوف یزید خطر تعرّضك لنوبات صرع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">مثل جمیع الأدوی ة، یمكن أن یسبّب ھذا الدواء تأثیرات جانبیةّ لا تصیب المرضى كلھّم.<br />استشر الطبیب أو الصیدلي على الفور إذا أصبت بأيّ من التأثیرات الجانبیةّ الآتیة :<br />&bull; إصابة في الكبد (التھاب الكبد) أو البنكریاس (التھاب البنكریاس) مما قد یكون خطیرًا ومھدداً للحیاة، ویمكن أن یبدأ<br />فجأة مع تعب وفقدان الشھیّة وإرھاق ونعاس وغثیان وتقیّؤ وألم في البطن.<br />&bull; ارتكاس تحسسي:<br />تورّم مفاجئ في الوجھ و/أو العنق یمكن أن یسبّب صعوبة في التنف س وقد یھددّ الحیاة (أودیما كوینك)، o<br />ارتكاس تحسسيّ خطیر (تناذر فرط الحساسیّة تجاه الدواء) یتضمّن عدّة أعراض مثل الحمى والطفح الجلدي o<br />وتضخّم العقد اللمفاویةّ وتلف الكبد وتلف الكلى ونتائج غیر طبیعیةّ لفحوصات الدم مثل زیادة عدد بعض كریات<br />الدم البیضاء (الحمضات).<br />&bull; طفح جلدي مع بثور أحیانًا قد یصیب الفم أیضًا (الحمامى المتشكّلة)، بثور مع انقلاع للجلد یمكن أن ینتشر بسرعة على<br />الجسم كلّھ ویمكن أن یھدّد الحیاة (تناذر لیل، تناذر ستیفنز جونسون).<br />تأثیرات جانبیةّ أخرى محتملة:<br />&bull; تشوّھات خلقیةّ واضطرابات في النموّ الذھني وا لجسديّ (راجع في القسم 2 &quot; الحمل والإرضا ع والخصوبة &quot;).<br />:( شائعة جدًا (تُصیب أكثر من شخص واحد من أصل 10<br />&bull; غثیان،<br />&bull; رجفة.<br />:( شائعة (تصُیب حتىّ شخص واحد من أصل 10<br />&bull; في بدایة العلاج: تقیؤّ، أوجاع في المعدة، إسھال،<br />&bull; زیادة في الوزن ،<br />&bull; أوجاع في الرأس ،<br />&bull; نعاس،<br />&bull; اختلاجات،<br />&bull; اضطرابات في الذاكرة،<br />&bull; تشوّش ذھنيّ، عدائیّة، انفعال، اضطرابات في الانتباه، ھلوسات (رؤیة أشیاء غیر موجودة أو سماعھا أو الشعور بھا)،<br />&bull; اضطرابات خارج الھرمیةّ (مجموعة من الأعراض مثل الرجفة وتیبسّ الأعضاء وصعوبة السیر)*<br />&bull; السلس البولي (عدم القدرة على إمساك البول)،<br />&bull; حركات سریعة ولا یمكن التحكّم بھا في العینین،<br />&bull; فقدان السمع،<br />&bull; اضطرابات في اللثّة بخاصة زیادة حجم اللثّة (تضخّم اللثّة) ،<br />&bull; ألم وتورّم وتقرّحات في الفم وشعور بحریق في الفم (التھاب الفم)،<br />&bull; تساقط الشعر،<br />&bull; اضطرابات في الدورة الشھریّة (عدم انتظام الحیض) ،<br />نزف،<br />&bull; أحاسیس بالغثیان أو الدوار ،<br />&bull; اضطرابات في الأظافر ومھد الأظافر،<br />&bull; انخفاض عدد الصفیحات (قلّة الصفیحات)، انخفاض عدد الكریات الحمراء (فقر دم)،<br />&bull; انخفاض كمیّة الصودیوم في الدم (نقص صودیوم الدم، متلازمة الإفراز غیر الملائم للھرمون المضاد لإدرار البول).<br />:( غیر شائعة (تُصیب حتّى شخص واحد من أصل 100<br />&bull; اضطرابات في الیقظة یمكن أن تصل إلى الغیبوبة العابرة، تتراجع بعد تخفیض الجرعة أو إیقاف العلاج،<br />&bull; صعوبة في تنسیق الحركات،<br />&bull; متلازمة باركنسون عكوسة*،<br />&bull; خدر أو تنمّل في الیدین والقدمین،<br />&bull; ملمس غیر طبیعي للشعر، تغییرات في لون الشعر، نموّ غیر طبیعي للشعر،<br />&bull; طفح بثور أو بقع على الجلد ،<br />&bull; نموّ الشعر الزائد، بخاصة لدى النساء، ترجیل، حب الشباب (فرط الأندروجینیة)،<br />&bull; انخفاض حرارة الجسم ،<br />&bull; تورّم الأطراف (أودیما)،<br />&bull; انقطاع الطمث (غیاب الدورة الشھریّة)،<br />&bull; زیادة عدد الاختلاجات وخطورتھا، ظھور نوبات اختلاجیةّ من نوع مختلف،<br />&bull; صعوبة في التنفّس وألم یعود إلى تورّم الغشاء الواقي للرئتین (الانصباب الجنبي)،<br />&bull; انخفاض مجموع خلایا الدم: الكریات البیضاء والكریات الحمراء والصفیحات (قلّة الكریات الشاملة)، انخفاض عدد<br />الكریات البیضاء (نقص الكریات البیضاء)،<br />&bull; أفید عن حالات من الاضطرابات العظمیةّ تظھر عبر ھشاشة العظام (نقص العظام)، انخفاض الكتلة العظمیةّ (ترقق<br />العظام) وعن كسور.<br />استشر الطبیب أو الصیدلي في حالة العلاج الطویل الأمد بدواء مضاد للصرع، أو في حالة إصابة سابقة بترقق العظام<br />أو أخذ ستیرویدات قشریة،<br />&bull; التھاب الأوعیة الدمویةّ.<br />:( نادرة (تصُیب حتىّ شخص واحد من أصل 1000<br />&bull; صعوبة على الإبقاء على البول (التبوّل اللاإرادي) ،<br />&bull; اضطرابات في الخصوبة لدى الرجال تكون عمومًا قابة للزوال على الأقلّ 3 أشھر بعد إیقاف العلاج ومن المحتمل أن<br />تكون قابلة للزوال بعد تخفیض الجرعة. لا توقف علاجك قبل استشارة الطبیب أوّلا ،<br />&bull; خلل في وظیفة المبیضین (متلازمة المبیض المتعدد الكیسات)،<br />&bull; اضطرابات في السلوك، زیادة النشاط النفسي الحركي، صعوبات في التعلّم،<br />&bull; ارتكاس مناعيّ ذاتيّ مع ألم في المفاصل، طفح جلدي وحمى (ذئبة حمامیة منتشرة)،<br />&bull; انخفاض نشاط الغدةّ الدرقیّة (قصور الغدةّ الدرقیّة) ،<br />&bull; آلام عضلیةّ وضعف عضلي یمكن أن یكون خطیرًا (انحلال الربیدات)،<br />&bull; بدانة،<br />&bull; إصابة الكلى (قصور كلويّ، التھاب الكلیة النبیبي الخلالي، متلازمة فانكوني)،<br />&bull; زیادة حجم كریات الدم الحمراء (كبر الكریات)، انخفاض كبیر في عدد الكریات البیضاء (ندرة المحببات)،<br />&bull; فقدان إنتاج خلایا الدم (فقر الدم اللاتنسجي)، إنتاج غیر طبیعي لخلایا الدم (خلل التنسج النخاعي) ،<br />،(...TCA إطالة ،INR &bull; انخفاض عوامل التخثرّ، اختبارات تخثرّ غیر طبیعیةّ (ارتفاع<br />&bull; انخفاض كمیةّ الفیتامین ب 8 (بیوتین)/بیوتینیداز،<br />&bull; ارتفاع كمیةّ الأمونیا في الدم،<br />&bull; ازدواج الرؤیة،<br />&bull; اضطرابات في الذاكرة وفي القدرات الذھنیّة تظھر تدریجیًا (اضطرابات معرفیّة، متلازمة العتھ)*، تخفّ بعد بضعة<br />أسابیع إلى بضعة أشھر من إیقاف العلاج.<br />لا توقف علاجك قبل التحدّث إلى طبیبك أوّلاً.<br />*یمكن أن تكون ھذه الأعراض مرتبطة بعلامات إشعاعیةّ على مستوى الدماغ (ضمور الدماغ).<br />تأثیرات جانبیةّ إضافیةّ لدى الأطفال<br />تكون بعض التأثیرات الجانبیّة للفالبروات أكثر شیوعًا لدى الأطفال أو أكثر خطورة لدى البالغین. ویؤدي ھذا إلى إصابة<br />الكبد، والتھاب البنكریاس، والعدائیةّ، والانفعال، واضطراب في الانتباه، وسلوك غیر طبیعيّ، وفرط حركة واضطراب في<br />التعلمّ.<br />الإبلاغ عن التأثیرات الجانبیةّ<br />للإبلاغ عن أيّ عارض (أعراض) جانبيّ (ة):<br />&bull; المملكة العربیةّ السعودیةّ:<br />- المركز الوطني للتیقظّ الدوائي وسلامة الأدوی ة<br />&bull; مركز الاتصال للھیئة العامة للغذاء والدواء: 19999<br />npc.drug@sfda.gov.sa : &bull; البرید الإلكتروني<br />https://ade.sfda.gov.sa/ : &bull; الموقع الإلكتروني<br />KSA_Pharmacovigilance@sanofi.com : &bull; سانوفي &ndash; قسم التیقظّ الدوائي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ ھذا الدواء بعیدًا عن نظر ومتناول الأطفال.<br />لا تستعمل ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العلبة. یشیر تاریخ انتھاء الصلاحیةّ إلى الیوم الأخیر من<br />الشھر المذكور.<br />لا ترمِ الأدویة في مصرف المیاه أو مع النفایات المنزلیة العادیة. اطلب من الصیدلي التخلصّ من الأدویة التي لم تعد تستعملھا،<br />فمن شأن ھذه الإجراءات حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفاعلة ھي :<br />فالبروات الصودیوم................................................................................................................ 20,00 غ<br />ل 100 مل.<br />یساوي مل واحد من المحلول 200 ملغ من فالبروات الصودیوم.<br />&bull; المركّبات الأخرى ھي:<br />یوریا، محلول ھیدروكسید الصودیوم 30 % وماء منقّى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>یأتي ھذا الدواء على شكل محلول للشرب. قارورة من 40 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسویق<br />Sanofi-Aventis france</strong><br />82, avenue Raspail<br />94250 Gentilly, France<br /><br /><strong>المصنعّ<br />Unither Liquid Manufacturing</strong><br />1-3, allee de la Neste<br />31770 Colomiers, France or<br /><strong>Sanofi Winthrop Industrie</strong><br />30-36, avenue Gustave Eiffel<br />37100 Tours, France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            30 يناير 2025
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Depakine 200 mg/mL oral solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sodium valproate .......................................................................................................................... 20.00 g
For 100 mL.
1 mL of solution is equivalent to 200 mg of sodium valproate.
This medicinal product contains sodium (see section 4.4).
Excipient with known effect: sodium.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>In adults:</strong></u> either as single-agent therapy, or in combination with another antiepileptic treatment:<br />&bull; Treatment of generalised epilepsy: clonic, tonic, tonic-clonic, absence, myoclonic and atonic seizures, and Lennox-Gastaut syndrome.<br />&bull; Treatment of partial epilepsy: partial seizures with or without secondary generalisation.<br /><u><strong>In children:</strong></u> either as single-agent therapy, or in combination with another antiepileptic treatment:<br />&bull; Treatment of generalised epilepsy: clonic, tonic, tonic-clonic, absence, myoclonic and atonic seizures, and Lennox-Gastaut syndrome.<br />&bull; Treatment of partial epilepsy: partial seizures with or without secondary generalisation.<br /><u><strong>In children:</strong></u><br />&bull; Prevention of recurrence of seizures after 1 or more febrile convulsions that meet the criteria for complicated febrile convulsions, when intermittent benzodiazepine prophylaxis has failed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Female children and women of childbearing potential<br />Valproate must be initiated and supervised by a specialist experienced in the management of epilepsy.<br />Valproate should not be used in female children and women of childbearing potential unless other treatments are ineffective or not tolerated. In this case, valproate is prescribed and dispensed according to the Valproate Pregnancy Prevention Programme (see sections 4.3 and 4.4).<br />Among the oral pharmaceutical forms, the syrup, oral solution and prolonged-release granules are more appropriate for administration to children less than 11 years.<br /><u><strong>Posology</strong></u><br />Mean daily dose:<br />&bull; Infants and children: 30 mg/kg (syrup, oral solution or prolonged-release granules should preferably be used).<br />&bull; Adolescents and adults: 20 to 30 mg/kg (tablets, prolonged-release tablets or prolonged-release granules should preferably be used).<br />The medicinal product should be prescribed only in milligrams.<br />The bottle of oral solution is supplied with an oral syringe. The graduation marks indicate doses in milligrams (mg) (1 graduation mark every 25 mg, from 50 mg to 400 mg).<br /><u><strong>Patients with renal insufficiency</strong></u><br />It may be necessary to decrease the dosage in patients with renal insufficiency, and it may be necessary to increase the dosage in patients on dialysis. Sodium valproate is dialysable (see section 4.9). Dosage should be adjusted according to clinical monitoring of the patient (see section 4.4).<br /><u><strong>Method of administration Oral route.</strong></u><br />The oral solution should only be administered using the oral syringe (pink plunger) supplied in the box.<br />The daily dose should preferably be administered during meals:<br />&bull; as 2 divided doses in patients under 1 year of age, &bull; as 3 divided doses in patients over 1 year of age.<br />The solution should be drunk after diluting in a small amount of non-carbonated drink.<br /><em><u>Initiation of treatment</u></em><br />&bull; If the patient is already being treated and is taking other antiepileptics, treatment with sodium valproate should be initiated gradually, to reach the optimal dose in approximately 2 weeks, then the concomitant treatments reduced if necessary on the basis of treatment efficacy.<br />&bull; If the patient is not taking any other antiepileptics, the dosage should preferably be increased stepwise every 2 or 3 days, in order to reach the optimal dose in approximately 1 week.<br />&bull; If necessary, combination treatment with other antiepileptics should be instituted gradually (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Pregnancy unless there is no suitable alternative treatment (see sections 4.4 and 4.6).
• Women of childbearing potential, unless the conditions of the Pregnancy Prevention Programme are fulfilled (see sections 4.4 and 4.6).
• History of hypersensitivity to valproate, valproate semisodium, valpromide or to any of the excipients listed in section 6.1.
• Acute hepatitis.
• Chronic hepatitis.
• Patient or family history of severe hepatitis, especially drug-related.
• Hepatic porphyria.
• Patients with known urea cycle disorders (see section 4.4).
• Valproate is contraindicated in patients known to have mitochondrial disorders caused by mutations in the nuclear gene encoding mitochondrial enzyme polymerase gamma (POLG), e.g. AlpersHuttenlocher Syndrome, and in children under 2 years of age who are suspected of having a POLGrelated disorder (see section 4.4).
• Combination with St John’s Wort (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Special warnings<br />Pregnancy Prevention Programme</strong></u><br />Valproate has a high teratogenic potential and children exposed in utero to valproate have a high risk for congenital malformations and neuro-developmental disorders (see section 4.6). Valproate should not be used in female children and women of childbearing potential unless other treatments are&nbsp;ineffective or not tolerated. If no other treatment is possible, the Pregnancy Prevention Programme below must be complied with.<br />Depakine is contraindicated in the following situations:<br />&bull; In pregnancy unless there is no suitable alternative treatment (see sections 4.3 and 4.6). &bull; In women of childbearing potential, unless the conditions of the Pregnancy Prevention Programme are fulfilled (see sections 4.3 and 4.6). <em><u>Conditions of the Pregnancy Prevention Programme</u></em> The prescriber must ensure that:<br />&bull; individual circumstances should be evaluated in each case, involving the patient in the discussion, to guarantee her engagement, discuss therapeutic options and ensure her understanding of the risks and the measures needed to minimise the risks.<br />&bull; the potential for pregnancy is assessed for all female patients.<br />&bull; the patient has understood and acknowledged the risks of congenital malformations and neuro-developmental disorders including the magnitude of these risks for children exposed to valproate in utero.<br />&bull; the patient understands the need to undergo pregnancy testing prior to initiation of treatment and during treatment, as needed.<br />&bull; the patient is counselled regarding contraception, and that the patient is capable of complying with the need to use effective contraception (for further details please refer to subsection contraception of this boxed warning), without interruption during the entire duration of treatment with valproate.<br />&bull; the patient understands the need for regular (at least annual) review of treatment by a specialist experienced in the management of epilepsy.<br />&bull; the patient understands the need to consult her physician as soon as she is planning pregnancy to ensure timely discussion and switching to alternative treatment options prior to conception, and before contraception is discontinued.<br />&bull; the patient understands the need to urgently consult her physician in case of pregnancy.<br />&bull; the patient has received the Patient Guide.<br />&bull; the patient has acknowledged that she has understood the hazards and necessary precautions associated with valproate use (Annual Risk Acknowledgment Form).<br />These conditions also concern women who are not currently sexually active unless the prescriber considers that there are compelling reasons to indicate that there is no risk of pregnancy.<br /><em><u>Female children</u></em><br />&bull; The prescriber must ensure that parents/caregivers of female children understand the need to contact the specialist once the female child using valproate experiences menarche.<br />&bull; The prescriber must ensure that parents/caregivers of female children who have experienced menarche are provided with comprehensive information about the risks of congenital malformations and neuro-developmental disorders including the magnitude of these risks for children exposed to valproate in utero.<br />&bull; In patients who experienced menarche, the prescribing specialist must reassess the need for valproate therapy annually and consider alternative treatment options. If valproate is the only suitable treatment, the need for using effective contraception and all other conditions of the Pregnancy Prevention Programme should be discussed. Every effort should be made by the specialist to switch the female children to alternative treatment before they reach puberty or adulthood.<br /><em><u>Pregnancy test</u></em><br />Pregnancy must be excluded before start of treatment with valproate. Treatment with valproate must not be initiated in women of childbearing potential without a negative result from a plasma pregnancy test with a sensitivity of at least 25 mIU/mL, confirmed by a healthcare provider, to rule out unintended use in pregnancy. This pregnancy test must be repeated at regular intervals during treatment.<br /><em><u>Contraception</u></em><br />Women of childbearing potential who are prescribed valproate must use effective contraception, without interruption during the entire duration of treatment with valproate. These patients must be&nbsp;provided with comprehensive information on pregnancy prevention and should be referred for contraceptive advice if they are not using effective contraception. At least 1 effective method of&nbsp;contraception (preferably a user-independent form such as an intra-uterine device or implant) or 2 complementary forms of contraception including a barrier method should be used. Individual circumstances should be evaluated in each case when choosing the contraception method, involving the patient in the discussion, to guarantee her engagement and compliance with the chosen measures. Even if she has amenorrhea she must follow all the advice on effective contraception.<br /><em><u>Oestrogen-containing products</u></em><br />Concomitant use with oestrogen-containing products, including oestrogen-containing hormonal contraceptives, may result in decreased valproate efficacy (see section 4.5). Prescribers should monitor clinical response (seizure control) when initiating or discontinuing oestrogen-containing products.<br />However, valproate does not reduce efficacy of hormonal contraceptives.<br /><em><u>Annual treatment reviews by a specialist</u></em><br />The specialist should at least annually review whether valproate is the most suitable treatment for the patient. The specialist should discuss the Annual Risk Acknowledgment Form at initiation and during each annual review and ensure that the patient has understood its content. The Annual Risk Acknowledgment Form must be duly completed and signed by the prescriber and patient (or her legal representative).<br /><em><u>Pregnancy planning</u></em><br />If a woman is planning to become pregnant, a specialist experienced in the management of epilepsy must reassess valproate therapy and consider alternative treatment options. Every effort should be made to switch to appropriate alternative treatment prior to conception, and before contraception is discontinued (see section 4.6). If switching is not possible, the woman should receive further counselling regarding the valproate risks for the unborn child to support her informed decision-making regarding family planning.<br /><em><u>In case of pregnancy</u></em><br />If a woman using valproate becomes pregnant, she must be immediately referred to a specialist to re-evaluate treatment with valproate and consider alternative options. The patients with a valproate-exposed pregnancy and their partners should be referred to a specialist experienced in teratology for evaluation and counselling regarding the exposed pregnancy (see section 4.6).<br /><em><u>Pharmacists must ensure that</u></em><br />&bull; the Patient Card is provided with every valproate dispensing and that the patients understand its content.<br />&bull; the patients are advised not to stop valproate medication and to immediately contact a specialist in case of planned or suspected pregnancy.<br /><em><u>Educational materials</u></em><br />In order to assist healthcare professionals and patients in avoiding exposure to valproate during pregnancy, the Marketing Authorisation Holder has provided educational materials to reinforce the warnings concerning the teratogenicity (congenital malformations) and fetotoxicity (neurodevelopmental disorders) of valproate and provide guidance regarding use of valproate in women of childbearing potential and the details of the Pregnancy Prevention Programme. A Patient Guide and Patient Card should be provided to all women of childbearing potential using valproate.<br />An Annual Risk Acknowledgment Form needs to be used and duly completed and signed at the time of treatment initiation and during each annual review of valproate treatment by the specialist and the patient (or her legal representative).<br /><em><u>Exacerbation of seizures</u></em><br />As with other antiepileptics, administration of valproate may, instead of improvement, lead to a reversible exacerbation of seizure frequency and severity (including status epilepticus), or the onset of a new type of seizure. Patients should be advised to consult their physician immediately if exacerbation of seizures&nbsp;occurs (see section 4.8). These seizures should be differentiated from those that may occur due to a pharmacokinetic interaction (see section 4.5), toxicity (liver disease or encephalopathy - see sections 4.4 and 4.8) or overdose.<br />Since this medicinal product is metabolised into valproic acid, it should not be combined with other medicinal products undergoing the same transformation to avoid an overdose of valproic acid (e.g. valproate semisodium, valpromide).<br /><em><u>Severe liver damage</u></em><br /><strong>Conditions of occurrence</strong><br />Severe liver damage resulting sometimes in fatalities has exceptionally been reported.<br />Patients most at risk are infants and young children under the age of 3 years with severe seizure disorders, particularly those with brain damage, mental retardation and/or congenital metabolic or degenerative disease. After the age of 3 years, the risk is significantly reduced and it progressively decreases with age.<br />In most cases, such liver damage occurred during the first 6 months of therapy, usually between the 2nd and 12th week and generally during antiepileptic polytherapy.<br /><strong>Suggestive signs</strong><br />Clinical symptoms are essential for early diagnosis. In particular, the 2 conditions which may precede jaundice should be taken into consideration, especially in patients at risk (see &ldquo;Conditions of occurrence&rdquo;):<br />&bull; firstly, non-specific symptoms, usually of sudden onset, such as asthenia, anorexia, lethargy, drowsiness, which are sometimes associated with repeated vomiting and abdominal pain.<br />&bull; secondly, recurrence of epileptic seizures despite proper treatment compliance.<br />Patients (or their family for children) should be instructed to report immediately any such signs to a physician should they occur. Investigations including clinical examination and laboratory assessment of liver functions should be undertaken immediately.<br /><strong>Detection</strong><br />Liver function tests should be performed before therapy and regularly during the first 6 months of therapy, especially in patients at risk.<br />If concomitant treatments known for their liver toxicity are changed (dose increase or new treatment), liver function tests must be carried out again (see also section 4.5 on the risk of liver damage with salicylates, other anticonvulsants including cannabidiol).<br />Among the usual investigations, tests which reflect protein synthesis, particularly prothrombin rate, are most relevant. Confirmation of an abnormally low prothrombin rate, particularly in association with other biological abnormalities (significant decrease in fibrinogen and coagulation factors; increased bilirubin level and raised transaminases &ndash; see section &ldquo;Precautions for use&rdquo;) requires cessation of therapy with this medicinal product (as a matter of precaution and in case they are taken concomitantly, salicylate derivatives should also be discontinued since they follow the same metabolic pathway).<br /><em><u>Pancreatitis</u></em><br />Pancreatitis, which may result in fatalities, has been very rarely reported. Young children are at particular risk but this can be observed irrespective of age and treatment duration.<br />Pancreatitis with an unfavourable outcome is generally observed in young children or in patients with severe seizures, neurological impairment or anticonvulsant polytherapy.<br />Hepatic failure with pancreatitis increases the risk of fatal outcome.<br />In the event of acute abdominal pain or gastrointestinal signs such as nausea, vomiting and/or anorexia, a diagnosis of pancreatitis must be considered and, in patients with elevated pancreatic enzymes, treatment discontinued, and the necessary alternative therapeutic measures implemented.<br /><em><u>Suicidal ideation and behaviour</u></em><br />Suicidal ideation and behaviour have been reported in patients treated with antiepileptics in several indications. A meta-analysis of data from randomised, placebo-controlled trials of antiepileptic drugs has&nbsp;also shown a slight increase in risk of suicidal ideation and behaviour. The causes of this risk are unknown and the available data do not make it possible to rule out an increased risk with valproate.<br />Therefore, patients should be closely monitored for signs of suicidal ideation and behaviour, and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.<br /><em><u>Patients with known or suspected mitochondrial disease</u></em><br />Valproate may trigger or worsen clinical signs of underlying mitochondrial diseases caused by mutations of mitochondrial DNA as well as the nuclear gene encoding the mitochondrial enzyme polymerase gamma (POLG).<br />In particular, acute liver failure and liver-related deaths have been associated with valproate treatment at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations in the POLG gene, e.g. Alpers-Huttenlocher Syndrome.<br />POLG-related disorders should be suspected in patients with a family history or suggestive symptoms of a POLG-related disorder, including but not limited to unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus at presentation, developmental delays, psychomotor regression, axonal sensorimotor neuropathy, myopathy, cerebellar ataxia, ophthalmoplegia, or complicated migraine with occipital aura. POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders (see section 4.3).<br /><em><u>Interaction with other medicinal products</u></em><br />Coadministration of this medicinal product with lamotrigine and/or penems (carbapenems) is not recommended (see section 4.5).<br /><em><u>Cognitive or extrapyramidal disorders</u></em><br />Cognitive or extrapyramidal disorders can be associated with imaging findings of cerebral atrophy. This type of clinical picture can thus be confused with dementia or Parkinson&rsquo;s disease. These disorders are reversible on treatment discontinuation (see section 4.8).<br /><em><u>Information related to the sodium content</u></em><br />This medicinal product contains 28 mg sodium per 200 mg sodium valproate, equivalent to 1.4% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This must be taken into account in patients following a strict low-sodium diet.<br /><u><strong>Precautions for use</strong></u><br />Liver function tests should be performed before starting therapy (see section 4.3) and then periodically during the first 6 months, particularly in patients at risk (see section 4.4 &ldquo;Severe liver damage &ndash; Detection&rdquo;).<br />It should be emphasised that, as with most antiepileptic drugs, a moderate, transient and isolated increase in liver enzymes may be noted without any clinical signs, particularly at the beginning of the therapy.<br />More extensive biological investigations (including prothrombin rate) are recommended in this case; an adjustment of dosage may be considered when appropriate and tests should be repeated as necessary.<br />Blood tests (blood cell count, including platelet count, bleeding time and coagulation parameters) are recommended prior to treatment, then after 15 days and at the end of treatment or before surgery, and in case of spontaneous bruising or bleeding (see section 4.8).<br />In patients with renal insufficiency, elevated circulating valproic acid concentrations in the blood should be taken into account and the dosage should be reduced accordingly.<br />This medicinal product is contraindicated in patients with urea cycle enzyme deficiencies. A few cases of hyperammonaemia with stupor or coma have been described in these patients (see section 4.3).<br />Although immune disorders have been noted only exceptionally during the use of this medicinal product, its potential benefit should be weighed against its potential risk in patients with systemic lupus erythematosus.<br />Patients should be warned of the risk of weight gain at the initiation of therapy and appropriate strategies should be adopted to minimise the risk.&nbsp;<br />Since valproate is excreted mainly in the urine partly in the form of ketone bodies, ketone body excretion test may give false positive results in diabetic patients.<br />Patients with carnitine palmitoyltransferase (CPT) type II deficiency should be warned of the greater risk of rhabdomyolysis when taking valproate.<br />Alcohol intake is not recommended during treatment with Depakine.<br /><em><u>Children</u></em><br />Monotherapy is recommended in children under the age of 3 years when prescribing valproate, but the potential benefit should be weighed against the risk of liver damage or pancreatitis in such patients prior to initiation of therapy (see section 4.4 &quot;Severe liver damage&quot; and section 4.5).<br />The simultaneous prescription of salicylates should be avoided in children under 3 years due to the risk of hepatotoxicity (see also section 4.4) and the risk of bleeding.<br />In children with a history of unexplained hepatic and gastrointestinal disorders (anorexia, vomiting, acute episodes of cytolysis), episodes of lethargy or coma, mental retardation or with a family history of neonatal or infant death, metabolic tests and, in particular, fasting and post-prandial blood ammonia tests must be performed prior to any valproate treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Contraindicated combinations</strong></u><br /><strong>+ St. John&#39;s Wort</strong><br />There is a risk of decreased plasma concentrations and reduced efficacy of the antiepileptic.<br /><strong><u>Inadvisable combinations</u><br />+ Lamotrigine</strong><br />There is a higher risk of serious skin reactions (toxic epidermal necrolysis).<br />Furthermore, an increase in lamotrigine plasma concentrations may occur (decreased hepatic metabolism by sodium valproate).<br />If coadministration proves necessary, close clinical monitoring is required.<br /><strong>+ Penems (carbapenems)</strong><br />There is a risk of seizures due to a rapid decrease in valproic acid plasma concentrations, which may become undetectable.<br />Co-administration of valproic acid and carbapenems has led to decreases in plasma concentrations of valproic acid of approximately 60 to 100% in around two days. Due to the rapid onset and the extent of the decreased plasma concentrations, simultaneous administration of carbapenems in patients stabilised on valproic acid who cannot be monitored should therefore be avoided (see section 4.4).<br /><strong><u>Combinations requiring precautions for use</u><br />+ Acetazolamide</strong><br />Increased hyperammonaemia with increased risk of encephalopathy may occur.<br />Regular monitoring of clinical and laboratory parameters is required.<br /><strong>+ Aztreonam</strong><br />There is a risk of seizures due to a decrease in valproic acid plasma concentrations.<br />Clinical monitoring, plasma assays and possible dose adjustment of the anticonvulsant are required during treatment with the anti-infective agent and after its discontinuation.<br /><strong>+ Carbamazepine</strong><br />Increased plasma concentrations of the active metabolite of carbamazepine with signs of overdose may occur. In addition, reduced valproic acid plasma concentrations may occur due to its increased hepatic metabolism by carbamazepine.<br />Clinical monitoring, plasma assays and dose adjustment of both anticonvulsants are required.<br /><strong>+ Felbamate</strong><br />Increased serum valproic acid concentrations with a risk of overdose may occur.<br />Clinical monitoring and monitoring of laboratory parameters and possible valproate dose adjustment are required during treatment with felbamate and after its discontinuation.<br /><strong>+ Oestrogen-containing products, including oestrogen-containing hormonal contraceptives</strong><br />Oestrogens are inducers of the UDP-glucuronosyl transferase (UGT) isoforms involved in valproate glucuronidation and may increase valproate clearance, which in turn is thought to cause a decrease in serum valproate concentrations and to potentially reduce valproate efficacy (see section 4.4). Consider monitoring valproate serum levels.<br />Conversely, valproate has no enzyme-inducing effect; as a consequence, valproate does not reduce the efficacy of oestroprogestative agents in women receiving hormonal contraception.<br /><strong>+ Metamizole</strong><br />Metamizole may decrease valproate serum levels when co-administered, which may result in potentially decreased valproate clinical efficacy.<br />Prescribers should monitor clinical response (seizure control or mood control) and consider monitoring valproate serum levels as appropriate.<br /><strong>+ Nimodipine (oral route and, by extrapolation, by injection)</strong><br />There is a risk of a 50% increase in plasma nimodipine concentrations. Therefore, nimodipine dose reduction is necessary in hypotensive patients.<br /><strong>+ Phenobarbital, and by extrapolation primidone</strong><br />Increased hyperammonaemia with increased risk of encephalopathy may occur.<br />Regular monitoring of clinical and laboratory parameters is required.<br /><strong>+ Phenytoin, and by extrapolation fosphenytoin</strong><br />Increased hyperammonaemia with increased risk of encephalopathy may occur.<br />Regular monitoring of clinical and laboratory parameters is required.<br /><strong>+ Propofol</strong><br />A possible increase in propofol blood levels may occur. When co-administered with valproate, a reduction in propofol dose should be considered.<br /><strong>+ Rifampicin</strong><br />There is a risk of seizures due to increased hepatic metabolism of valproate by rifampicin.<br />Clinical monitoring and monitoring of laboratory parameters and possible anticonvulsant dose adjustment are required during treatment with rifampicin and after its discontinuation.<br /><strong>+ Rufinamide</strong><br />A possible increase in rufinamide concentrations may occur, in particular in children weighing less than 30 kg.<br />In children weighing less than 30 kg: the total dose of 600 mg/day after dose titration should not be exceeded.<br /><strong>+ Topiramate</strong><br />Increased hyperammonaemia with increased risk of encephalopathy may occur.<br />Regular monitoring of clinical and laboratory parameters is required.<br /><strong>+ Zidovudine</strong><br />There is a risk of increased adverse effects of zidovudine, particularly haematological effects, due to decrease in its metabolism by valproic acid.<br />Regular monitoring of clinical and laboratory parameters is required. A blood count should be performed to test for anaemia during the first 2 months of the combination.<br /><strong>+ Zonisamide</strong><br />Increased hyperammonaemia with increased risk of encephalopathy may occur.<br />Regular monitoring of clinical and laboratory parameters is required.<br /><u><strong>Other forms of interaction</strong></u><br /><strong>+ Lithium</strong><br />Depakine has no effect on serum lithium levels.<br /><strong>+ Risk of liver damage</strong><br />The concomitant use of salicylates should be avoided in children under 3 years due to the risk of liver toxicity (see section 4.4).<br />Concomitant use of valproate and other anticonvulsants increases the risk of liver damage, especially in young children (see section 4.4).<br />Concomitant use with cannabidiol increases the incidence of raised transaminases. In patients of all ages receiving concomitantly cannabidiol at doses of 10 to 25 mg/kg and valproate, clinical trials have reported ALT increases greater than 3 times the upper limit of normal in 19% of patients. Appropriate liver monitoring should be exercised when valproate is used concomitantly with other anticonvulsants with potential hepatotoxicity, including cannabidiol. Dose reductions or therapy cessation should be considered in case of significant anomalies of liver parameters (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valproate is contraindicated (see sections 4.3 and 4.4):<br />&bull; during pregnancy unless there is no suitable alternative treatment.<br />&bull; in women of childbearing potential, unless the conditions of the Pregnancy Prevention Programme are fulfilled.<br /><u><strong>Pregnancy</strong></u><br /><em><u>Teratogenicity and neuro-developmental effects</u></em><br />Both valproate monotherapy and valproate polytherapy including other antiepileptics are frequently associated with abnormal pregnancy outcomes. Available data show an increased risk of major congenital malformations and neurodevelopmental disorders in both valproate monotherapy and polytherapy compared to the population not exposed to valproate. Valproate was shown to cross the placental barrier both in animal species and in humans (see section 5.2). In animals, teratogenic effects have been demonstrated in mice, rats and rabbits (see section 5.3).<br /><u><strong>&bull; Congenital malformations</strong></u><br />A meta-analysis (including registries and cohort studies) showed that about 11% of children of epileptic women exposed to valproate monotherapy during pregnancy had major congenital malformations. This is greater than the risk of major malformations in the general population (about 2-3%).<br />The risk of major congenital malformations in children after in utero exposure to anti-epileptic polytherapy including valproate is higher than that of anti-epileptic drugs polytherapy not including valproate.<br />This risk is dose-dependent in valproate monotherapy, and available data suggest it is dose-dependent in valproate polytherapy. However, a threshold dose below which no risk exists cannot be established.<br />Available data show an increased incidence of minor and major malformations. The most common types of malformations include neural tube defects (approximately 2-3%), facial dysmorphism, cleft lip and palate, craniostenosis, cardiac, renal and urogenital defects (in particular, hypospadias), limb defects (including bilateral aplasia of the radius), and multiple anomalies involving various body systems.<br />In utero exposure to valproate may also result in hearing impairment/loss due to ear and/or nose malformations (secondary effect) and/or to direct toxicity on the hearing function. Cases describe both unilateral and bilateral deafness or hearing impairment. Outcomes were not reported for all cases. When outcomes were reported, the majority of the cases had not resolved.<br />In utero exposure to valproate may result in congenital eye disorders (including coloboma and microphthalmia), which were reported together with other congenital malformations. These congenital eye disorders may affect visual ability.<br /><u><strong>&bull; Neuro-developmental disorders</strong></u><br />Studies have shown that exposure to valproate in utero increases the risk of neuro-developmental disorders in exposed children. The risk of neurodevelopmental disorders (including that of autism) seems to be dose-dependent when valproate is used in monotherapy but a threshold dose below which no risk exists, cannot be established based on available data.<br />When valproate is administered in polytherapy with other anti-epileptic drugs during pregnancy, the risks of neurodevelopment disorders in the offspring were also significantly increased as compared with those in children from general population or born to untreated epileptic mothers.<br />The period of risk for these effects is uncertain and the possibility of a risk throughout the entire pregnancy cannot be excluded.<br />When valproate is administered in monotherapy, studies in pre-school children exposed in utero to valproate show that up to 30-40% experience delays in their early development such as talking and walking later, lower intellectual abilities, poor language skills (speaking and understanding) and memory problems.<br />Intelligence quotient (IQ) measured in school-aged children (aged 6) with a history of valproate exposure in utero was on average 7-10 points lower than those children exposed to other antiepileptics. Although the role of confounding factors cannot be excluded, there is evidence in children exposed to valproate in utero that the decrease in IQ may be independent from maternal IQ.<br />There are limited data on the long-term outcomes.<br />Available data from a population-based study show that children exposed to valproate in utero are at increased risk of autism spectrum disorders (approximately 3-fold) and childhood autism (approximately 5-fold) compared with the unexposed study population.<br />Available data from another population-based study show that children exposed to valproate in utero are at increased risk of developing attention deficit/hyperactivity disorder (ADHD) (approximately 1.5fold) compared with the unexposed study population.<br /><em><u>Women of childbearing potential</u></em><br />Depakine should not be used in women of childbearing potential unless other treatments are ineffective or not tolerated. If no other treatment is possible, Depakine can only be initiated if the Pregnancy Prevention Programme is complied with (see section 4.4), in particular:<br />&bull; the patient is not pregnant (plasma pregnancy test with a sensitivity of at least 25 mIU/mL negative at the start of treatment and at regular intervals during treatment).<br />&bull; the patient is using at least 1 effective method of contraception.<br />&bull; and the patient is informed of the risks associated with using valproate during pregnancy.<br />In women of childbearing potential, the benefit-risk balance must be carefully re-evaluated at regular intervals during treatment (at least annually).<br />Oestrogen-containing products&nbsp;Oestrogen-containing products, including oestrogen-containing hormonal contraceptives, may increase the clearance of valproate, which may result in decreased serum concentration of valproate and potentially decreased valproate efficacy (see sections 4.4 and 4.5).<br /><em><u>If a woman plans a pregnancy</u></em><br />If a woman is planning to become pregnant, a specialist experienced in the management of epilepsy must reassess valproate therapy and consider alternative treatment options. Every effort should be made to switch to appropriate alternative treatment prior to conception, and before contraception is discontinued (see section 4.4). If switching is not possible, the woman should receive further counselling regarding the valproate risks for the unborn child to support her informed decision-making regarding family planning.<br />&bull; Folate supplementation before pregnancy and at the beginning of pregnancy may decrease the risk of neural tube defects common to all pregnancies. However, the available evidence does not suggest it prevents the birth defects or malformations due to valproate exposure.<br /><em><u>Pregnant women</u></em><br />Valproate as treatment for epilepsy is contraindicated in pregnancy unless there is no suitable alternative treatment (see sections 4.3 and 4.4).<br />If a woman using valproate becomes pregnant, she must be immediately referred to a specialist to consider alternative treatment options. During pregnancy, maternal tonic-clonic seizures and status epilepticus with hypoxia may carry a particular risk of death for mother and the unborn child.<br />If, despite the known risks of valproate in pregnancy and after careful consideration of alternative treatment, in exceptional circumstances a pregnant woman must receive valproate for epilepsy:<br />&bull; the lowest effective dose must be used<br />&bull; the daily dose of valproate should be divided into several small doses to be taken throughout the day. The use of a prolonged-release formulation may be preferable to other treatment formulations in order to avoid high peak plasma concentrations (see section 4.2).<br />All patients with a valproate-exposed pregnancy and their partners should be referred to a specialist experienced in teratology for evaluation and counselling regarding the exposed pregnancy.<br />&bull; Specialised prenatal monitoring should take place to detect the possible occurrence of neural tube defects or other malformations.<br /><em><u>Before delivery</u></em><br />Coagulation tests should be performed in the mother before delivery, including in particular a platelet count, fibrinogen levels and coagulation time (activated partial thromboplastin time: aPTT).<br /><u>Risk in the neonate</u><br />&bull; Cases of haemorrhagic syndrome have been reported very rarely in neonates whose mothers have taken valproate during pregnancy. This haemorrhagic syndrome is related to thrombocytopenia, hypofibrinogenemia and/or to a decrease in other coagulation factors. Afibrinogenemia has also been reported and may be fatal. However, this syndrome must be distinguished from the decrease of the vitamin-K factors induced by phenobarbital and enzymatic inducers. Normal haemostasis test results in the mother do not make it possible to rule out haemostasis abnormalities in the neonate. Therefore, platelet count, fibrinogen plasma level, coagulation tests and coagulation factors should be investigated in neonates at birth.<br />&bull; Cases of hypoglycaemia have been reported in neonates whose mothers have taken valproate during the third trimester of their pregnancy.<br />&bull; Cases of hypothyroidism have been reported in neonates whose mothers have taken valproate during pregnancy.<br />&bull; Withdrawal syndrome (in particular, agitation, irritability, hyper-excitability, jitteriness, hyperkinesia, tonicity disorders, tremor, convulsions and feeding disorders) may occur in neonates whose mothers have taken valproate during the last trimester of their pregnancy.<br /><em><u>Post-natal monitoring/monitoring of children</u></em><br />Close monitoring of the neuro-developmental behaviour must be implemented in children exposed to valproate during pregnancy and suitable treatment initiated as early as possible if necessary.<br /><u><strong>Breast-feeding</strong></u><br />Valproate is excreted in human milk with a concentration ranging from 1% to 10% of maternal serum levels. Haematological disorders have been shown in breast-fed newborns/infants of treated women (see section 4.8).<br />A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Depakine therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.<br /><u><strong>Fertility</strong></u><br />Amenorrhoea, polycystic ovaries and increased testosterone levels have been reported in women treated with valproate (see section 4.8). In men, the administration of valproate may also impair fertility (reduced sperm motility in particular) (see section 4.8). In some cases, these fertility disorders are reversible after discontinuing treatment for at least 3 months. In a limited number of cases, it was reported that a significant reduction in dosage can improve fertility. However, in other cases, the reversibility of this male infertility is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The attention of patients, particularly those who drive or use machines, must be drawn to the risk of drowsiness, especially in patients receiving anticonvulsant polytherapy or concomitant administration with other medicinal products that may increase drowsiness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Very common (&ge; 10%); common (&ge; 1% to &lt; 10%); uncommon (&ge; 0.1% to &lt; 1%); rare (&ge; 0.01% to &lt; 0.1%); very rare (&lt; 0.01%); not known (cannot be estimated from the available data).<br /><u><strong>Congenital, familial and genetic disorders</strong></u><br />&bull; Congenital malformations and neuro-developmental disorders (see sections 4.4 and 4.6).<br /><u><strong>Blood and lymphatic system disorders</strong></u><br />&bull; Common: anaemia, thrombocytopenia.<br />&bull; Cases of dose-dependent thrombocytopenia have been reported, generally discovered systematically and without any clinical repercussions.<br />&bull; In patients with asymptomatic thrombocytopenia, if possible, given the platelet level and control of the disease, simply reducing the dose of this medicinal product usually leads to resolution of thrombocytopenia.<br />&bull; Uncommon: leukopenia, pancytopenia.<br />&bull; Rare: bone marrow aplasia or pure red cell aplasia, agranulocytosis, macrocytic anaemia, macrocytosis.<br /><u><strong>Investigations</strong></u><br />&bull; Common: weight gain*.<br />&bull; Rare: decrease in at least 1 coagulation factor, abnormal coagulation tests (such as prolonged prothrombin time, prolonged activated partial thromboplastin time, prolonged thrombin time, prolonged INR) (see sections 4.4 and 4.6), vitamin B8 (biotin) deficiency/biotinidase deficiency.<br />*as weight gain is a risk factor for polycystic ovary syndrome, patient weight must be carefully monitored (see section 4.4).<br /><u><strong>Nervous system disorders</strong></u><br />&bull; Very common: tremor<br />&bull; Common: extrapyramidal disorders**, stupor*, sedation, seizures*, memory impairment, headache, nystagmus, nausea or dizziness.<br />&bull; Uncommon: coma*, encephalopathy*, lethargy*, reversible parkinsonism**, ataxia, paraesthesia,<br />&bull; Rare: diplopia, cognitive disturbances of insidious and progressive onset (which may progress as far as complete dementia) and which are reversible a few weeks to a few months following treatment withdrawal**<br />*Cases of stupor and lethargy, sometimes leading to transient coma (encephalopathy), have been observed with valproate; they decreased on withdrawal of treatment or reduction of dosage. These cases mostly occurred during combined therapy (in particular with phenobarbital or topiramate) or after a sudden increase in valproate doses.<br />**These symptoms can be associated with imaging findings of cerebral atrophy.<br /><u><strong>Ear and labyrinth disorders</strong></u><br />&bull; Common: hearing loss.<br /><u><strong>Respiratory, thoracic and mediastinal disorders</strong></u><br />&bull; Uncommon: pleural effusion.<br /><u><strong>Gastrointestinal disorders</strong></u><br />&bull; Very common: nausea.<br />&bull; Common: vomiting, gingival disorders (mainly gingival hyperplasia), stomatitis, upper abdominal pain, diarrhoea that may occur in some patients at the start of treatment, but usually disappearing after a few days without discontinuing the treatment.<br />&bull; Uncommon: pancreatitis with possibly fatal outcome requiring early treatment discontinuation (see section 4.4).<br /><u><strong>Renal and urinary disorders</strong></u><br />&bull; Common: urinary incontinence.<br />&bull; Uncommon: renal failure.<br />&bull; Rare: enuresis, tubulointerstitial nephritis, reversible Fanconi syndrome.<br /><u><strong>Skin and subcutaneous tissue disorders</strong></u><br />&bull; Common: transient and/or dose-related alopecia, nail and nail bed disorders.<br />&bull; Uncommon: angioedema, skin reactions, hair disorders (such as abnormal hair texture, hair colour changes, abnormal hair growth).<br />&bull; Rare: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) or drug hypersensitivity syndrome.<br /><u><strong>Endocrine disorders</strong></u><br />&bull; Uncommon: inappropriate antidiuretic hormone secretion syndrome (IADHS), hyperandrogenism (hirsutism, virilism, acne, androgenetic alopecia and/or increase in androgen hormone levels).<br />&bull; Rare: hypothyroidism (see section 4.6).<br /><u><strong>Metabolism and nutrition disorders</strong></u><br />&bull; Common: hyponatremia.<br />&bull; Rare: hyperammonaemia* (see section 4.4), obesity.<br />*Cases of isolated and moderate hyperammonaemia without change in liver function tests may occur, especially during polytherapy, and should not cause treatment discontinuation.<br />However, cases of hyperammonaemia associated with neurological symptoms (which may progress to coma) have also been reported, and require further investigations (see section 4.4).<br /><u><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></u><br />&bull; Rare: myelodysplastic syndrome.<br /><u><strong>Vascular disorders</strong></u><br />&bull; Common: haemorrhage (see sections 4.4 and 4.8).<br />&bull; Uncommon: cutaneous vasculitis, mainly leukocytoclastic vasculitis.<br /><u><strong>General disorders and administration site conditions</strong></u><br />&bull; Uncommon: hypothermia, non-severe peripheral oedema.<br /><u><strong>Hepatobiliary disorders</strong></u><br />&bull; Common: liver disorders (see section 4.4).<br /><u><strong>Reproductive system and breast disorders</strong></u><br />&bull; Common: irregular menstruation.<br />&bull; Uncommon: amenorrhea.<br />&bull; Rare: male infertility (see section 4.6), polycystic ovaries.<br /><u><strong>Musculoskeletal and connective tissue disorders</strong></u><br />&bull; Uncommon: decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with Depakine. The mechanism of action of Depakine on bone metabolism is not known.<br />&bull; Rare: acute systemic lupus erythematosus (see section 4.4), rhabdomyolysis (see section 4.4).<br /><u><strong>Psychiatric disorders</strong></u><br />&bull; Common: confusional state, hallucinations, aggressiveness*, agitation*, attention disorders*.<br />&bull; Rare: abnormal behaviour*, psychomotor hyperactivity*, learning disabilities*.<br />*These effects are mainly observed in the paediatric population.<br /><u><strong>Paediatric population</strong></u><br />The safety profile of valproate in the paediatric population is comparable to adults, but some adverse reactions are more severe or principally observed in the paediatric population. There is a particular risk of severe liver damage in infants and young children especially under the age of 3 years. Young children are also at particular risk of pancreatitis. These risks decrease with increasing age (see section 4.4). Psychiatric disorders such as aggression, agitation, disturbance in attention, abnormal behaviour, psychomotor hyperactivity and learning disorder are principally observed in the paediatric population.<br /><u><strong>Reporting of suspected adverse reactions</strong></u><br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs of acute massive overdose usually include a calm coma, which may be more or less deep, with muscular hypotonia, hyporeflexia, miosis, impaired respiratory functions, metabolic acidosis, hypotension and circulatory collapse/shock.<br />A few cases of intracranial hypertension related to cerebral oedema have been described.<br />Patient management in a hospital setting includes: gastric lavage if indicated, maintenance of effective diuresis, cardiorespiratory monitoring. In very serious cases, renal replacement therapy may be performed if necessary.<br />The prognosis for such poisoning is generally favourable. However, a few deaths have been reported.<br />The sodium content in valproate-containing medicinal products can lead to hypernatremia in the event of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: ANTIEPILEPTICS, ATC code: N03AG01.</strong><br />Valproate is pharmacologically active primarily on the central nervous system.<br />The drug has an anticonvulsant effect on a very wide range of seizures in animals and epilepsy in humans.<br />Experimental and clinical studies on valproate suggest 2 types of anticonvulsant effect.<br />The first is a direct pharmacological effect related to valproate concentrations in the plasma and the brain.<br />The second appears to be indirect and is probably related to the metabolites of valproate, which remain in the brain, or to changes in neurotransmitters or direct membrane effects. The most widely accepted hypothesis is that of gamma-aminobutyric acid (GABA) levels, which increase following valproate administration.<br />Valproate reduces the duration of intermediate stages of sleep, with a concomitant increase in slow sleep.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The various pharmacokinetic studies conducted on valproate have shown that:<br />&bull; The bioavailability in the blood following oral administration is close to 100%.<br />&bull; The volume of distribution is mainly limited to the blood and to the rapid-exchange extracellular fluids. Valproate circulates in the CSF and in the brain.<br />&bull; Placental transfer (see section 4.6):<br />Valproate crosses the placental barrier in animal species and in humans:<br />o in animal species, valproate crosses the placenta to a similar extent as in humans, o in humans, several publications assessed the concentration of valproate in the umbilical cord of neonates at delivery. Valproate serum concentration in the umbilical cord, representing that in the foetuses, was similar to or slightly higher than that in the mothers.<br />&bull; The half-life is 15 to 17 hours.<br />&bull; Therapeutic efficacy usually requires a minimum serum concentration of 40 to 50 mg/L, with a wide range from 40 to 100 mg/L. If higher plasma levels prove necessary, the expected benefits must be weighed against the risk of occurrence of adverse effects, particularly dose-dependent effects. However, levels remaining above 150 mg/L require a dose reduction.<br />&bull; The steady-state plasma concentration is reached in 3 to 4 days.<br />&bull; Valproate is highly protein-bound. Protein binding is dose-dependent and saturable.<br />&bull; The major metabolic pathway of valproate is glucuronidation (approximately 40%), mainly via UGT1A6, UGT1A9 and UGT2B7.<br />&bull; Valproate is excreted mainly in the urine, following metabolisation by glucuronide conjugation and beta-oxidation.<br />&bull; Valproate can be dialysed, but haemodialysis only affects the free fraction of blood valproate (approximately 10%).<br />&bull; Valproate does not induce enzymes involved in the metabolic system of cytochrome P450, in contrast with most other antiepileptics. It therefore does not accelerate its own degradation or that of other substances, such as oestrogen-progestogens and oral anticoagulants.<br /><strong>Paediatric population</strong><br />Above the age of 10 years, children and adolescents have valproate clearances similar to those reported in adults. In paediatric patients below the age of 10 years, the systemic clearance of valproate varies with age. In neonates and infants up to 2 months of age, valproate clearance is decreased when compared to adults and is lowest directly after birth. In a review of the scientific literature, valproate halflife in infants under two months showed considerable variability ranging from 1 to 67 hours.<br />In children aged 2-10 years, valproate clearance is 50% higher than in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>abnormalities in the auditory systems of rats and mice.<br />In vitro, valproate was not mutagenic in bacteria, or in mouse lymphoma assays, and did not induce DNA repair activity in primary culture of rat hepatocytes. However, in vivo, contradictory results were obtained at teratogenic doses depending on the route of administration. After oral administration, the predominant route in humans, valproate did not induce either chromosome aberrations in rat bone marrow, or dominant lethal effects in mice. Intraperitoneal injection of valproate increased DNA strandbreaks and chromosomal aberrations in rodents. Furthermore, an increase in sister-chromatid exchange in epileptic patients exposed to valproate was reported in published studies compared with untreated healthy subjects. However, contradictory results were obtained when comparing the data for epileptic patients treated with valproate with the data for untreated epileptic patients. The clinical significance of these conclusions on DNA/chromosomes is unknown.<br />Non-clinical data from conventional carcinogenicity studies reveal no particular risk for humans.<br /><u><strong>Reproductive toxicity</strong></u><br />Valproate induced teratogenic effects (malformations of multiple organ systems) in mice, rats and rabbits.<br />Behavioural abnormalities have been reported in first generation offspring of mice and rats after in utero exposure. In mice, certain behavioural changes have also been observed in the 2nd and 3rd generations, albeit less pronounced in the 3rd generation, following an acute in utero exposure of the first generation at teratogenic doses of valproate. The underlying mechanisms and the clinical relevance of these findings are unknown.<br />In repeated dose toxicity studies, testicular degeneration/atrophy, abnormal spermatogenesis and a decrease in testes weight were reported in adult rats and dogs after oral administration starting at doses of 1 250 mg/kg/day and 150 mg/kg/day, respectively.<br />In juvenile rats, the decrease in testes weight was only observed at doses exceeding the maximum tolerated dose (from 240 mg/kg/day by intraperitoneal or intravenous route) and with no associated histopathological changes. No effects on the male reproductive organs were noted at tolerated doses (up to 90 mg/kg/day). Based on these data, juvenile animals were not considered to be more susceptible than adults to testicular disorders. Relevance of the testicular findings to paediatric population is unknown.<br />In a fertility study in rats, valproate administration at doses up to 350 mg/kg/day did not alter male reproductive performance. However, male infertility has been identified as an adverse reaction in humans (see sections 4.6 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Urea, 30% sodium hydroxide solution, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special precautions for storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>40 mL amber glass bottles with a polyethylene stopper.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SANOFI-AVENTIS FRANCE
82, AVENUE RASPAIL 94250 GENTILLY
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30-Jan-2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>